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1.	ABSTRACT	
This project details the investigation done to formulate insulin-loaded PLGA 
microparticles for responsive insulin delivery. The formulations are to be tested for 
glucose specificity as a function of particle porosity later on in the investigation. The 
glucose responsive characteristic of the PLGA microparticle was modulated via 
incorporation of 4-formylphenyl boronic acid (4-FPBA) through conjugation with 
chitosan. Boronic acid moieties present in 4-FPBA are known to be sensitive to diols, 
such as glucose and fructose and is used here to provide the glucose sensing characteristic 
of the PLGA microparticles while chitosan is used as the anchor and readily forms nano- 
and micro-particles through ionic gelation with a suitable cross-linkers. The conjugation 
of 4-FPBA and chitosan proceeded through the Schiff’s base method through N-reductive 
alkylation. The conjugates were characterized using Fourier transform infrared 
spectroscopy (FTIR), differential scanning calorimetry (DSC) and field emission 
scanning electron microscope (FESEM) analysis to ascertain the extend of bonding of the 
conjugate. The double solvent evaporation method was used to formulate porous and 
non-porous formulation. The non-porous formulation was found to be stable, discrete 
with no agglomeration seen through SEM analyses. Porosity was induced in the 
microparticle formulation through the use of parogens. Through optimization, stable and 
porous PLGA microparticles were formulated by enhancing the pores formed via 
exposure to ethanolic- NaOH. The glucose absorption of the PLGA microparticle 
samples was successfully measured through an indirect method utilising curcumin to 
detect 4-FPBA content in the microparticle sample. It was found that the increase in 
surface area afforded by the porous PLGA microparticle caused more of the 4-FPBA 
tagged chitosan to be incorporated within particles which resulted in higher 4-FPBA 
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content readily available in the porous microparticle sample. The higher 4-FPBA content 
correlates to a higher glucose sensitivity for the porous PLGA microparticles as observed 
in the higher insulin release profile obtained when compared to the non-porous 
microparticles. Porosity plays a vital role in increasing the glucose responsivity of the 
microparticles as the porous microstructure exposes more 4-FPBA to glucose and hence 
enhance the reactivity, allowing more of the incorporated insulin to be release as a 
consequence. 
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1. INTRODUCTION	
2.1 Background		
Hyperglycaemia otherwise known as diabetes mellitus is one of the most common 
metabolic disorder that has seen a rapid increased in patients numbers around the world 
in the last decade (Chakraborty et al. 2011). Diabetes mellitus is commonly categorised 
as ‘Type 1’ and ‘Type 2 cases’. Type 1 diabetes manifests when the patient suffers from a 
deficiency of insulin leading to high blood sugar levels. The insufficient levels of insulin 
produced by the pancreas in Type 1 cases are thought to be due to the destruction of 
insulin-producing beta cells of the islets of Langerhans by autoimmune responses (Owens 
et al. 2016). On the other hand, type 2 diabetes is due to disorders in both insulin 
resistance and secretion caused by defects in the insulin receptors on the cell membranes 
(Owens et al. 2016). Of the two, Type 2 cases are the more common with approximately 
90% of people diagnosed with diabetes mellitus having this type of diabetes (American 
Diabetes Association 2013).  
Patients living with type 2 diabetes specifically require constant monitoring of blood 
glucose level that is regulated through a regimented lifestyle which includes modified 
dietary sugar intake, regular physical exercise as well as insulin therapy in the form of 
subcutaneous administration of insulin (American Diabetes Association 2012). However, 
insulin therapy in this manner results in a number of disadvantages including 
hypoglycaemia whereby the level of glucose in the bloodstream drop below the normal 
level as well as obesity due to intensive therapy, insulin neuropathy which is 
characterised by acute severe distal limb pain and in rare cases, insulin presbyopia 
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whereby patient may be visually impaired (farsightedness) due to dependence on insulin 
therapy (Sharma et al. 2015). In addition and with particular importance to the present 
research pursuit is that current administration of insulin employ up to four subcutaneous 
injections per day, causing psychological distress to the patient and leading to poor 
patient compliance (Carino et al. 2000). 
These aforementioned drawbacks provide a challenge to researchers for exploration of 
possibilities that may improve upon the existing conventional modes of delivery in order 
to improve the quality of life of suffers. Significant research has already been done which 
focuses on alternative routes of administration such as oral and pulmonary as well as 
ways to reduce the number of injectable doses to mitigate the drawbacks associated with 
conventional insulin treatment. While development of oral insulin formulation shows 
promise, major constraints  to this mode of delivery include both enzymatic and physical 
barriers (Carino et al. 2000). Insulin, being proteinous, is prone to degradation by  gastric 
acidity and intestinal enzymes  when  administered orally which consequently 
substantially decreases the bioavailability of the total insulin administered (Lowman et al. 
2016). In addition, the relatively short half-life  coupled with the fragile nature of  orally 
formulated insulin are additional barriers that need to be overcome in order for orally-
administered insulin therapy to be viable (Sharma et al. 2015). As such, the development 
of a commercial orally-based insulin delivery system has remained elusive. 
Recently however, there is an increased interest in the development of micro- and 
nanoparticle drug delivery systems since these can be engineered to address some of the 
aforementioned constrains. Thus, it is not surprising that the development alternative 
insulin delivery systems seem to be harnessed around this technology. The use of 
microparticle and nanoparticle for drug delivery applications provides numerous 
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advantages over conventional methods and depending on the route of administration may 
include increased  efficacy tolerability due to fewer doses and lesser dose cargo from the 
delivery system specificity and therapeutic index of the analogous drug (Hall et al. 2007). 
These advantages can further be enhanced by modifying the surface of the drug loaded 
nanoparticle or microparticle by conjugation with specific moieties that  impart either 
passive or active targeting of specific cells or tissue (Singh & Lillard Jr. 2009). In 
addition, nano- and microparticles provide alternative pathways to the delivery of 
partially water-soluble drugs in an effective manner as well as targeting drugs to specific 
regions of the gastrointestinal tract. Indeed, studies have shown that the increased surface 
area of the small particles is exceedingly effective for targeted drug delivery (Chiranjib et 
al. 2013). In terms of health and safety, materials used to construct nanoparticles or 
microparticles, have to be stable, biodegradable, non-toxic, non-inflammatory and be able 
to escape the reticuloendothelial system when injected internally (Kumari et al. 2010).  
Recent studies have shown that numerous polymeric and micellar nanocarriers provide 
desirable biopharmaceutical and pharmacokinetic properties in regards to insulin (Sharma 
et al. 2015). Studies done indicate several nanocarriers formulations suitable for insulin 
delivery include poly(lactic-co-glycolic acid) (PLGA) nanoparticles, detran-insulin 
nanoparticles and solid lipid-insulin nanoparticles (Sharma et al. 2015). Thus, insulin 
incorporated into these micro- and nanocarriers for selective and targeted delivery may 
provide better therapeutic outcomes in the treatment of diabetic patients by eliminating 
some of the drawbacks associated with the conventional treatment. This forms the core 
basis of the present work, whereby we aim to develop a potential insulin-containing 
microparticle delivery system taking into account the nature of materials used, which in 
this case are biodegradable and biocompatible, but also to drive along the premise of 
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reduced dosing frequency and sensitivity. Put together, these would address head-on the 
aforementioned constrained associated with current mode of insulin delivery. 
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2.2 	Literature	Review	
This study focuses on the formulation of porous and non-porous insulin-loaded PLGA 
microparticles that have been tuned for glucose specificity in insulin release. PLGA 
polymers are popular in controlled drug delivery due to their excellent biodegradability, 
favourable degradation characteristic and sustained drug release capability which can be 
controlled by varying the molecular weight or the lactide/glycolide ratio of the polymer 
(Hirenkumar & Siegel 2012). Figure 1 shows the repeating ester units within the PLGA 
polymer chain. PLGA is also an FDA approved biomaterial that undergoes 
biodegradation after ingestion forming lactic and glycolic acids which are classified as 
non-toxic substances (Hirenkumar & Siegel 2012). Biodegradation of PLGA occurs 
mainly through hydrolysis but conflicting reports also shows the enzymatic degradation 
may also play a role (Hirenkumar & Siegel 2012). The lactic acid produced from this 
degradation process enters the tricarboxylic acid cycle before being eliminated from the 
body as carbon dioxide and water (Crotts & Park 1998). Similarly, glycolic acid also 
enters the tricarboxylic acid cycle and is eliminated from the body as carbon dioxide and 
water or alternatively, can be excreted in the kidney (Crotts & Park 1998).  
 
Figure	1:	Repeating	unit	in	PLGA	polymer	matrix 
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Polyester PLGA is  regarded as the best defined biomaterial available for drug delivery 
with respect to design and performance (Birnbaum et al. 2000). This is due to the 
versatile nature of the polyester which can be processed into a wide variety of shapes and 
sizes as well as able to encapsulate molecules of varying molecular size (Hirenkumar & 
Siegel 2012). In addition, PLGA is soluble in a wide range of solvents including acetone, 
chlorinated solvents, and ethyl acetate among others which provides an advantage over 
other polymers during nanoparticle formulation (Birnbaum et al. 2000).  
Documented studies have shown favourable data regarding the encapsulation of insulin 
PLGA nanoparticles. For example, Sun et al. (2010) prepared PLGA nanoparticles 
loaded with insulin-S.O (sodium oleate) complex via the double emulsion method to 
evaluate the pharmacological effects of oral administration to diabetic rats (Sun et al. 
2010). The study found that the glucose levels in rats was reduced considerably after oral 
administration. In another study by Liu et al. (2007) insulin encapsulated PLGA 
nanoparticles were embedded into poly(vinyl alcohol) (PVA) hydrogels where, it was 
suggested that the composite system minimised the burst release of insulin from the 
nanoparticle, providing a more sustained release of the drug (Liu et al. 2007). In addition, 
numerous other studies conducted with insulin loaded PLGA nanoparticles are under-way 
to ascertain the potential advantages afforded by this polymer in oral based-drug delivery 
system (Zhang et al. 2012). These studies unequivocally show the potential of PLGA 
nanoparticles as an effective drug delivery system for insulin.  
While PLGA particulates have been widely documented in drug delivery applications, 
there are potential drawbacks of utilising this polymer in targeted drug delivery. One 
drawback is that the surface charge of nano- microparticles particles from the polymer is 
slightly negative which limits the bioactivity when the nanoparticle interacts with the cell 
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membrane. This is because the cell membrane is also negatively charged and so can 
easily react more easily with more cationic particles to further facilitate endocytosis 
which is slightly hindered in the anionic polymer (Sharma et al. 2015). More importantly, 
due to the repeating ester units within the polymer chain whose activity is rather low 
(Figure 1), the surface of resulting particles tend to be passive and therefore active 
targeting of drug loaded PLGA nanoparticles is also difficult to achieve (Wang et al. 
2013). This drawback has restricted the number of studies done with regards to targeted 
PLGA microparticles and nanoparticles in drug delivery applications unless some surface 
modification intervention is pursued. There have been a number of attempts to 
functionalise the surface of PLGA nanoparticles by coating with more reactive moieties 
(Guo & Gemeinhart 2008; Wang, Z et al. 2010; Wang, Y et al. 2013). Through this 
approach, the targeting capability of micro- and nanoparticles is possible.  
Another widely used polymer in drug delivery applications is chitosan which can be 
found in shells of crustacean, the cuticles of insect and the cell wall of some fungi. 
Chitosan is composed of  naturally occurring cationic polysaccharides and is the subject 
of many bioengineering applications as it is biodegradable and biocompatible as well as  
non-toxic (Ding et al. 2003). The chemical structure of chitosan is shown in figure 2. As 
with PLGA, chitosan can be formulated into tablets, microspheres, nanoparticles and 
membranes for drug delivery carriers (Sharma et al. 2015). In addition, chitosan can also 
be formulated to form films easily (Wang et al. 2013). Indeed, multiple studies have 
shown the viability of coating chitosan unto PLGA nanoparticles in an attempt to 
functionalise the surface of the nanoparticle (Guo & Gemeinhart 2008; Wang, Z et al. 
2010; Wang, Y et al. 2013). For example, studies done by Wang et al. (2013) showed 
that the surface of PLGA nanoparticle drug delivery carrier can be functionalised by 
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coating with chitosan polymer (Wang et al. 2013). This was done by both physical 
desorption and chemical binding methods whereby the conventional double emulsion 
solvent evaporation method was modified slightly to incorporate chitosan into the 
formulation. The study concluded that PLGA modified by chitosan showed improved 
efficacy of 5-fluorouracil (5-FU) over non modified PLGA nanoparticles with a higher 
cumulative release of the drug in the same prolonged time (Wang et al. 2013). In another 
study by Wang et al. (2010), they  formulated  a tri-methylated chitosan-conjugated 
PLGA nanoparticle for the delivery of 6-coumarin across the blood-brain barrier (BBB) 
which further corroborated their previous result whereby the surface modified PLGA 
nanoparticle showed better efficacy of the loaded drug compared to non-modified PLGA 
nanoparticle (Wang et al. 2010). This change is brought about primarily due to the poly-
cationic nature of chitosan which when coated upon the surface of the slightly negative 
surface charge on PLGA nanoparticle, causes the overall surface charge of the 
nanoparticle to be positive (Figure 2). As a consequence, there is increased interaction 
between the particles and the cell membrane which enhances the process of endocytosis 
(Sharma et al. 2015). Both studies and indeed most literature regarding chitosan coated 
PLGA nanoparticles show the versatility of the modified nanoparticle. The reactivity of 
microparticles was enhanced by coating with chitosan so that it was possible to conjugate 
specific moieties to the chitosan modified PLGA microparticles (Wang et al. 2013).  
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Figure	2:	Chemical	structure	of	chitosan 
In the present study, glucose sensitivity was the desired objective and hence, the 
formulated PLGA microparticles requires moiety with this functionality. 4-
formylphenylboronic acid (4-FPBA) which is documented to be sensitive to glucose 
absorption was conjugated to pure unmodified chitosan. Boronic acid and their 
derivatives have been used extensively in analytical and signalling chemistry as sensing 
diol moieties to detect glucose and is only just recently used in drug delivery applications 
specifically, in the formulation of glucose sensitive chitosan nanoparticles (Hall 2011; 
Siddiqui et al. 2017). In a related study to the present work, conjugation of 4-FPBA and 
chitosan was shown to be successful  via a  Schiff base through N-reductive alkylation of 
the amine groups in the chitosan backbone (Asantewaa et al. 2013; Siddiqui et al. 2017).  
In addition, the report also showed that the glucose absorption characteristic of 4-FPBA 
was relatively unhindered in the modified chitosan, except at very high boronic acid 
loading (Asantewaa et al. 2013). The conjugation of chitosan and boronic acid moieties is 
discussed in further detail in the next chapter. As in previous studies we report successful 
glucose sensitivity after conjugation of phenyl boronic acid with chitosan, and coating on 
PLGA microparticles.  
Glucose sensitive phenylboronic acid (PBA) containing polymers shows promise in 
recent years due to its low cost, non-immunogenic and better in-vivo stability with a 
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range of glucose responsive material based upon PBA and its derivatives have been 
reported (Hall 2011). However, a major drawback of utilising these formulations in drug 
delivery is limited sustained drug release afforded with maximum period of only 2-5 days 
before additional application is required (Wu et al. 2017). On the other hand, PLGA 
based drug loaded nanoparticles and microparticles which offer a more sustained drug 
release profile as well as providing high loading capacity, encapsulation efficiency and 
favourable degradation characteristics provide an attractive co-polymer in PBA based 
glucose responsive drug delivery materials (Wu et al. 2017). The difficulty in 
functionalising the surface of the PLGA particle as mentioned previously forms a 
roadblock in forming these glucose sensitive PLGA microparticles, thus limiting the 
potential for glucose targeted PLGA microparticles. The novelty of this study is to 
provide an avenue to combine the properties of glucose responsivity in PBA based 
material and its derivatives with that of the versatile nature of PLGA based particulates 
through the use of chitosan coating. The relative ease of formulation through chitosan 
coating also provide an alternative to the more resource intensive controlled 
polymerization in order to instil targeting capability of PLGA micro- and nanoparticles. 
Another important aspect of the present study was to formulate both porous and non-
porous insulin loaded microparticle in order to ascertain the influence of porosity on 
glucose sensitivity of the microparticles and hence insulin release. Presumably, porous 
microparticles are likely to offer an improvement in sensitivity to glucose due to the 
larger surface area compared to non-porous microparticles but the converse may also be 
true because of the likely leakiness of insulin from porous microparticles, which 
compromise on the cargo load (Arayne & Sultana 2006). Furthermore, slow release 
capability is possible from non-porous microparticles. The non-porous microparticles 
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also offer a large surface area due to the relatively smaller size dimension. Therefore, it is 
worth investigating to see how these two types of microparticles responds to external 
glucose concentrations. Hence, the main aim of the present proposal was to investigate 
how the surface area provided by the porosity from the porous microparticles as well as 
the smaller size dimension from the non-porous microparticles match-up with regards to 
sensitivity to glucose and hence insulin release. Previous studies based on a related theme 
show that porous nanoparticles manifested a faster but more sustained release of the 
analogous drug as compared to non-porous nanoparticles (Oh et al. 2011; Ilyas et al. 
2013). Furthermore, investigations by Oh et al. (2011) on budesonide-loaded porous 
PLGA microparticles concluded that the percentage cumulative drug release was 
dependent upon the level of  porosity of the particle (Oh et al. 2011). It must be added 
that the distinctive feature in the present proposal is that there is a trigger for drug 
(insulin) release, which adds to the mix of possibilities. 
PLGA nanoparticles specifically benefits from porosity caused by accelerated polymer 
degradation from autocatalytic effects. When PLGA polymer is formulated into 
nanoparticles, the acids generated through hydrolytic reaction diffuses out of the particle. 
Furthermore, bases present in the bulk fluid diffuse into the nanoparticle, neutralising the 
acids. However, as the diffusional mass transport of these basses are relatively slow, the 
rate at which acids is generated within the nanoparticle can be much higher than the rate 
at which it is neutralized. Consequently, this leads to a decrease in the pH micro-
environment within the particle (Siepmann et al. 2005). This in turn leads to an 
accelerated polymer degradation through autocatalysis which affects both drug mobility 
and release rate (Siepmann et al. 2005). In porous systems, the porosity of the particle 
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increases the diffusivity of water- soluble molecules from the polymeric matrices which 
reduces the autocatalytic effect (Fan & Singh 1989).  
Studies by Ilyas et al. (2013) showed that an increase in size for drug loaded porous 
nanoparticles would result in a reduction in the relative release rates due to increase in 
length of diffusion pathways which decreases the rate of drug release to a more sustained 
profile (Ilyas et al. 2013). However, in the case of non-porous PLGA-based nanoparticle 
system, the increased diffusion pathway length effect is nullified due to autocatalysis 
effect resulting in unaltered drug release kinetics with increasing particle size (Klose et 
al. 2006). It can also be said that the pore characteristics have a significant impact on the 
underlying drug release mechanism as noted in a previous report whereby, porous PLGA 
nanoparticles showed better release behaviour due to the increase in available surface 
area for mass transfer (Arayne & Sultana 2006).   
In the present  study we focused on the formulation of microparticles which is defined as 
particulates having size range of approximately 2 to 2000 µm (Singh et al. 2017). 
Microparticles formulated for drug delivery applications offer identical advantages to 
nanoparticles such as effective protection of the drug cargo from enzymatic degradation, 
encapsulation of water soluble drugs, appropriately tuned to accurately control the release 
rate of the cargo as well as instilling passive and active targeting capabilities (Singh et al. 
2017). PLGA can be formulated to any size with relative ease and the preparation 
techniques are not too dissimilar from those of PLGA nanoparticles.  Previously  studies 
have shown that the double emulsion solvent evaporation method which is favoured for 
encapsulating hydrophilic drugs can be tuned to formulate either PLGA microparticles or 
nanoparticles by adjusting the disperse phase ratio and rate of stirring (Hirenkumar & 
Siegel 2012). This offers an avenue for fabrication of PLGA microparticles using 
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established protocols, whilst tuning relevant procedures in order to impart desirable 
characteristics such as porosity. 
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2.3 	Aims	and	Objectives	
The overarching aim of the present investigation was to formulate porous and non-porous 
PLGA polymeric microparticles for the purpose of glucose stimulated insulin release. 
The insulin loaded PLGA microparticles would be studied for glucose specificity and 
sensitivity with respect to porosity and size. Consequently, the following constitute the 
specific objectives for the study: 
I. Conjugation of boronic acid moiety (form of 4-formylphenylboronic acid (4-
FPBA) to chitosan. 
II. The formulation of both porous and non-porous insulin loaded PLGA 
microparticles made from above conjugates. III. To compare the extent of sensitivity to glucose between the two types of 
microparticles. 	IV. Subsequently, to study the relationships between glucose sensitivity and porosity 
as a function of insulin release. 	
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3 CONJUGATION	OF	PHENYLBORONIC	ACID	TO	CHITOSAN	TO	PRODUCE	GLUCOSE	SENSITIVE	CHITOSAN	
3.1 Introduction	
Recent developments on the capability of boronic-acid containing macromolecules has 
led to the advancement in key areas of biomedical applications such as saccharide 
sensing, controlled drug release and delivery of insulin, lipase inhibition as well as HIV 
inhibition to name a few (Fan & Singh 1989). Among these developments, significant 
attention has been given to the potential biological utility of boronic acid-conjugated 
polymers. These boronic acid- conjugated polymers are normally formulated into 
microgels or nanogels with specific properties such as thermal, glucose (saccharide), and 
pH responsiveness (Brooks & Sumerlin 2015). The degree or presence of these properties 
largely depend on the conjugated polymers chosen and can be tuned for a specific 
application as needed. For example, numerous studies on gels composed of 3-
acrylamidophenylboronic acid (APBA) and N-isopropylacrylamide (NIPAM) showed 
remarkable synergistic combination of sugar and temperature sensitivity (Guan & Zhang 
2013). In this case, sugar sensitivity is provided by the boronic acid moieties while the 
gel undergoes volume phase transition temperature inherent to the NIPAM co-polymer 
component (Guan & Zhang 2013). These properties designed for the hydrogels or 
microgels provide a strategy for applications in self-healing materials, drug delivery 
systems and saccharide sensors.  
Most boronic acid conjugated polymers contain the phenylboronic acid (PBA) moieties 
component.  An important characteristic of the boronic acid moieties is the ability of the 
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acid to form reversible complexes with 1,2 or 1,3 diols (Fan & Singh 1989). The 
formation of these complexes is due to the charged anionic tetrahedral form of the 
boronic acid in aqueous conditions which in the presence of a diol leads to stable 
boronate ester. Consequently, the conversion of neutral boronic acid moieties to anionic 
boronic ester causes the inherently hydrophobic property of boronic acid conjugated 
polymer to be more hydrophilic. This ‘diol-responsive’ behaviour of  boronic acid is 
integral in formulating effective delivery strategies as most boronic acid conjugated 
polymer systems developed for insulin delivery rely upon this change in hydrophilicity in 
response to the presence of compatible diols (Fan & Singh 1989). Thus, boronic acid 
containing hydrogels such as chitosan combine the merits of both boronic acid and 
hydrogel (Brooks & Sumerlin 2015). Glucose responsivity is attained by the introduction 
of boronic acid while the swelling properties and three-dimensional network is provided 
by the polymer used. 
Formulation of boronic acid conjugated polymers systems such as NIPAM occurs 
through controlled polymerization which is a resource intensive process that requires 
applications of heat and pressure to be successful (Brooks & Sumerlin 2015). 
Alternatively, with the use of chitosan polymer, boronic acid moieties can be directly 
linked to chitosan through reductive N-alkylation reaction of the reactive amine sites of 
the chitosan backbone (Smoum et al. 2006; Asantewaa et al. 2013). Essentially, the 
reaction is fairly similar to the reductive amination of aldehyde which involves the 
production of a carbinol amine which dehydrates to form an imine. The imine is then 
protonated utilizing an oxidising agent and subsequently reduction of this iminium ion 
([R1R2C=NR3R4]+) produces the alkylated amine product which in this study, is the 
successfully conjugated chitosan. Utilising reductive N-alkylation is advantageous as the 
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reaction proceeds under mild conditions at a relatively fast rate of reaction (Abdel-Magid 
et al. 1996). Combined with the ability of chitosan to form films easily especially with 
slightly anionic polymers like PLGA, glucose responsive boronic acid conjugated 
polymers can be made with relative ease. In the present  study we utilise 4-
formylphenylboronic acid (4-FPBA) due to previous reports indicating successful 
conjugation with chitosan was achieved utilising the Schiff base method (Asantewaa et 
al. 2013; Siddiqui et al. 2017).  
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3.2 Materials	and	Equipment	
Low molecular weight chitosan (50 – 190 kda) was purchased from Sigma Aldrich 
(St.Louis, MO, USA); 4-formylphenylboronic acid (4-FPBA) and sodium borohydride 
were purchased from Thermo Fisher Scientific (Bridgewater, NJ, USA); pure acetic acid, 
methanol  and ethanol were of reagent grade purchased from Thermo Fisher Scientific 
(Bridgewater, NJ, USA). 
 
The equipment used were Perkin Elmer FTIR spectrometer (Spectrum RX1, PerkinElmer 
Ltd, United Kingdom) Field Emission scanning electron microscopy (FESEM) equipped 
with an Energy dispersive x –ray detector (EDX) (Model Quanta 400F, FEI Company, 
USA), Mettler Toledo TGA Differential Scanning Calorimetry (DSC) system (Mettler-
Toledo (S) Pte Ltd, Singapore) and Beckman Benchtop Centrifuge (Allegra X-22R, 
Beckman Coulter, Inc., Indianapolis, USA). 
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3.3 	Methods	
3.3.1 	General	protocol	for	synthesis	of	conjugated	4-
formylphenylboronic	acid	(4-FPBA)	and	chitosan 
The protocol used for the N-reductive alkylation of the amine group within the chitosan 
backbone to facilitate conjugation of chitosan with 4-FPBA is as follows: 50 mg of 
chitosan (0.3 mmol of NH2) was dissolved in 5 ml of 1% acetic acid and the mixture was 
stirred for 1 hour. The required amount 4-FPBA for each formulation as shown in Table 1 
was dissolved in 15 ml methanol before being added into the chitosan solution. The 
mixture was stirred at 400 rpm using a magnetic stirrer for 1 hour under atmospheric 
pressure. The required amount of sodium borohydride (NaBH4) was added into the 
solution and continuously stirred for 24 hours at 300 rpm. After stirring, the mixture was 
poured into 50 ml centrifuge tubes. The precipitate was then collected by centrifugation 
for 10 minutes. The precipitate was washed with methanol, ethanol and water with 
centrifugation at 3 minute interval for each washing cycle. The samples were then frozen 
at -80 0C then freeze dried for 24 hours.  
Table	1:	Formulations	for	conjugated	4-FPBA	-Chitosan	
Formulation Chitosan 
(mg) 
Aldehyde 
Equivalent 
4-FPBA 
(mg) 
Sodium 
Borohydride 
(NaBH4) (mg) 
F1 50 1.5 67.5 27.2 
F2 50 2.0 89.9 36.3 
F3 50 2.5 112.4 45.4 
F4 50 3.0 134.9 54.5 
 
From Table 1, the amount of 4-FPBA required for each formulation was determined 
based upon the number  of moles of NH2 groups in chitosan (0.3 mmol of NH2 ) per 50 
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mg of chitosan (Smoum et al. 2006). By setting the aldehyde equivalent (moles of 4-
FPBA) to be a multiple of the moles of NH2 group in the chitosan sample, the amount of 
4-FPBA required for each sample can then be calculated. A sample calculation for F2 is 
shown in the following page. Furthermore, the amount of NaBH4 required for each 
formulation is equivalent to 1.6 times the moles of 4-FPBA added as per reports stating 
that successful conjugation of boronic acid to chitosan occurs when adequate amount of 
the oxidizing agent is present to precipitate the solid (Abdel-Magid et al. 1996). 
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Sample Calculation for F2 
 
For 4-FPBA,  50	$%	&'	(ℎ*+&,-. = 0.3	$$&2	&'	345	%6&78,	(:-,;<	&.	2*+;6-+76;)  
For aldehyde equivalence of 2.0,  0.3	×	2.0 = 0.6	))*+	*,	-+./ℎ1./  		"#	$%	4'()* = 	149.90	01$2-4  
From Elements of Chemical Reaction Engineering, Fourth Ed. (Fogler 2006),  ! = 	$%&&'(   ,  !"## = %	×	()  ……………………………………………...… (1) !"##	4&'()	*++,+, = 0.6	!!12	×	149.90  
                                      = 89.9	&'  
 
For Sodium Borohydride, 
Literature reported need equivalent of 1.6 times the moles of the boronic acid added,  !"#$%& = 0.6	×	1.6  																= 0.96	''()  
 !"	$%	&$'()*	+$,$ℎ.',('/	 = 	37.83	5*$6-1	  !"##	%&'()*	+&,&ℎ.',('/	,/0)(,/' = 0.96	**&6	×	37.83	*;**&6-=  
                                                                  = 	36.3	mg  
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3.3.2 	Modified	protocol for the synthesis of conjugated 4-
formylphenylboronic acid and chitosan  
It was found that the protocol presented in 3.31 did not yield a consistent trend over the 
four formulations studied. This is possibly due to insufficient amount of imine formation 
since the stirring after the addition of 4-FPBA into the chitosan solution only lasted for an 
hour. Subsequently, the protocol was modified as follows: firstly, the rate of stirring of 
the mixture containing chitosan and 4-FPBA in methanol was increased from 300 rpm to 
800 rpm in order to speed up the reaction rate and the stirring time was extended to 3 
hours. Previous studies reported successful reductive N-alkylation was accomplished by 
increasing the stirring time during imine formation (Abdel-Magid et al. 1996). 
Furthermore, the stirring time of the solution after addition of NaBH4 was decreased to 
only 10 minutes as significant precipitate was observed upon immediate addition of 
NaBH4 which is more in line with the other protocols reported.  
Three additional formulations were studied with increased boronic acid content. Table 2 
shows the additional formulations studied. 
 
Table	2:	Additional	formulation	for	conjugated	4-FPBA	-Chitosan	
Formulation Chitosan 
(mg) 
Aldehyde 
Equivalent 
4-FPBA 
(mg) 
Sodium 
Borohydride 
NaBH4 (mg) 
F5 50 4.0 180.0 72.6 
F6 50 8.0 360.0 145.3 
F7 50 16.0 720.0 290.5 
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In order to ascertain the extent of conjugation of 4-formylphenylboronic acid to chitosan, 
a number of analytical techniques were employed including, Fourier transform infra- red 
(FTIR) spectroscopy, differential scanning calorimetry (DSC) thermogram, enthalpy 
calculations and field emission scanning electron microscopy (FESEM) imaging. Each of 
these techniques are described in details below. 
 
3.3.3 Fourier	transform	infra-red	analysis	(FTIR) 
The FTIR spectra for all formulations as well as pure chitosan and pure 4-FPBA were 
obtained utilising a Perkin Elmer FTIR spectrometer. Prior to analysis, a small amount of 
the lyophilised sample was ground gently with approximately 250 mg of KBr powder 
until homogeneous powder was formed. The powder was then compressed under 6 
tonnes of pressure (6000 psi) using a pneumatic table press to form a disc. The spectra 
were collected between 4000- 400 cm-1, with each measurement done in triplicates. 
 
3.3.4 Differential	scanning	calorimetry	(DSC) 
The thermograms were obtained from a TGA-Differential Scanning Calorimeter (DSC) 
equipped with a TGA Universal Analysis software®. Briefly, 5 to 10 mg of the sample 
was placed in a standard aluminium pan, covered with a lid and crimped using the 
crimping equipment. The pan with closed lid was then placed on to the DSC heating 
stage and heated from 0 to 400 0C at a constant heating rate of 10 0C/min and under a 
constant purge of nitrogen gas at 20 ml/min. The sample was heated along with an empty 
pan as a reference. The thermogram of pure chitosan and pure 4-FPBA was also obtained 
for comparison. The TGA Universal Analysis® software was used to compare each 
formulation with respect to the thermograms obtained from pure chitosan and 4-FPBA.  
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3.3.5 Enthalpy	calculations	 
The enthalpy (DH) at each melting episode for each formulation was obtained from TGA 
Universal Analysis software. The DH is calculated from a typical DSC thermogram by 
integrating the area under the peak of the exothermic event. 
 
3.3.6 Field	Emission	Scanning	electron	microscopy	(FESEM)		 
A small amount of the lyophilised sample was placed unto an FESEM imaging stub. The 
sample was then viewed under the FESEM at 10.0 kV.  
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3.4 	Results	and	Discussion		
3.4.1 Formulation	of	4-FPBA-	chitosan	conjugate			 
The conjugation of 4-FPBA and chitosan relies upon the Scifff’s base whereby 4-FPBA 
was linked to chitosan through an N-reductive alkylation. This method is based upon a 
similar synthesis by Matsumoto et al. (2002) where researchers synthesised chitosan gel 
modified by phenylboronate for glucose absorption studies (Matsumoto et al. 2002). As 
mentioned earlier, this method involves the production of an imine intermediate which is 
further reduced to an amine upon addition of NaBH4. The overall reaction between 
chitosan and 4-FPBA through N-reductive alkylation reaction is shown in figure 3.  
 
Figure	3:	Overall	reaction	between	chitosan	and	4-formylphenylboronic	acid	(4-FPBA) 
 
Studies done by Smoum et al. (2006) on the conjugation of PBA to chitosan showed that 
the degree of N-substitution was dependent upon the aldehyde equivalent that was added 
into the mixture (Smoum et al. 2006).  Basically, conjugates with higher amount of 
boronic acid moieties can be formulated by simply increasing the amount of PBA in the 
reaction mixture.  
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3.4.2 FTIR	Analyses				 
The FTIR spectra of the formulations were compared with pure chitosan to ascertain any 
observable trend by the increased level of the aldehyde equivalent in the mixture. In the 
first approach described in section 3.3.1, the four formulations did not show any 
noticeable trend across the four samples as shown in Figure 4.  
 
 
Figure	4:	FTIR	spectra	of	formulations	F1	to	F4	with	respect	to	pure	chitosan	formulated	from	
protocols	described	in	3.3.1 
Notwithstanding, the characteristic peak  for chitosan at 3500 cm-1 corresponding to N-H 
bond stretching is seen in all formulations (Smoum et al. 2006). This is an important 
characteristic peak that may be used for identification once the chitosan-conjugated 
boronic acid is incorporated onto the PLGA microparticles. Further inspection shows that 
a clear peak is manifested at 1595 cm-1 in the spectrum for pure chitosan corresponding 
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to the primary amine NH2 vibration deformation (Smoum et al. 2006). This is an 
indication of successful conjugation of 4-FPBA to chitosan and the peak should gradually 
disappear as the degree of N-substitution should increase with increase in 4-FPBA in 
subsequent formulations as reported in previous studies (Asantewaa et al. 2013; Smoum 
et al. 2006). However, from Figure 4, it can be seen that only F2 and F3 produced peaks 
at 1560 cm-1 indicating the presence of substituted benzene, albeit minute intensity while 
also deemphasizing the primary amine peak. In contrast, F1 and F4 showed little to no 
observable changes compared to chitosan suggesting the conjugation was unsuccessful.  
The formation of imine is a reversible reaction and therefore the rate of reaction is 
considerably slow and does not proceed to completion if the reaction time is inadequate 
(Abdel-Magid et al. 1996). Hence, once the oxidizing agent was added to the mixture 
after a relatively short stirring time, the precipitate collected was the modified chitosan 
that failed to undergo a full N-reductive alkylation reaction. This resulted in F1 and F4 
having distinctly similar FTIR spectra with respect to pure unmodified chitosan as the 
boronic acid content in these conjugates were lower than expected. Thus, from the FTIR 
spectra produced from these four formulations, the conjugation of 4-FPBA to chitosan 
was deemed to be inconclusive. In this case, the stirring time of 1 hour and stirring speed 
of the mixture set at 300 rpm was recognized as the limiting factor. 
Modifications of the protocols described in 3.3.2 incorporates a longer stirring time of 3 
hours as well as increasing the stirring speed of the magnetic stirrer to 800 rpm to ensure 
the rate of reaction proceeds to completion and the formation of imine. The increase in 
stirring time has been reported to show better conjugation results (Abdel-Magid et al. 
1996). In addition, 3 additional formulations were studied to accurately convey the trend 
observed through the FTIR analyses. The samples were then compared with pure 4-
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FPBA as well as pure chitosan in order to fully characterize the differences between each 
formulation.  
The FTIR spectra formulations F1, F3, F5 and F7 are shown in Figure 5 with respect to 
4-FPBA and chitosan. The range of the spectra was adjusted to 2000 cm-1 to 400 cm-1 for 
ease of analysis. The FTIR spectra formulations F2, F4 and F6 are also shown in 
appendix 9.1.  
 
It can be seen in Figure 5 that the samples showed a more consistent trend than in the 
previous formulations (Figure 4). The characteristic peak corresponding to the primary 
amine of chitosan at 1590 cm-1 was observed to be less apparent from F1 through F7 
which suggest that 4-FPBA was successfully bonded to the primary amine site on the 
chitosan backbone. Further analysis of the spectra revealed that additional peaks were 
formed at 1560 cm-1, 1515 cm-1 and 816 cm-1 which further resolved into sharper peaks 
Figure	5:	Comparison	between	FTIR	spectra	of	formulations	F1,F3,	F5	and	F7	with	respect	to	pure	chitosan	and	4-
FPBA 
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from F1 to F7. These peaks correspond to the absorption bands of the para substituted 
benzene and support the evidence that the conjugation was successful and was brought 
about through the N-reductive alkylation reaction of the primary amine (Smoum et al. 
2006). 
When compared with pure 4-FPBA, the peaks corresponding to the  r - di- substituted 
benzene becomes sharper as the degree of N-substitution in the formulations were 
increased as seen in Figure 5. Indeed, the peaks of the samples starts to mimic those 
present in pure crystallised 4-FPBA specifically at 1560 cm-1 and 1515 cm-1 especially in 
F5 and F7.  This shows that there is a direct correlation between the intensity of the peaks 
and the degree of substitution achieved in the formulations as the conjugates with the 
highest degree of substitution manifested the highest peak intensity.  
From the FTIR spectra in Figure 5, it can be deduced that 4-FPBA has been successfully 
conjugated to chitosan through N-reductive alkylation. Comparisons with pure chitosan 
showed that the reactive site reside in the primary amine group as reported in several 
other studies (Asantewaa et al. 2013; Smoum et al. 2006). Comparison with pure 4-
FPBA showed that as the aldehyde equivalent was increased in each subsequent 
formulation, more of the boronic acid moieties were able to undergo N-reductive 
alkylation with chitosan which resulted in a higher degree of substitution in the 
conjugates.  
3.4.3 DSC	Analyses				 
Differential scanning calorimetric (DSC) analyses were conducted in order to observe the 
physical changes brought about after the successful conjugation of 4-FPBA to chitosan.  
As the degree of substitution increased, the modified chitosan showed a change in 
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material organization thereby changing the physical properties of the material. By 
utilizing DSC, these changes can be discerned.   
Figure 6 shows the DSC thermogram of pure chitosan. Chitosan was characterised by 
having two peaks, one endothermic peak and one exothermic peak. Similar result was 
reported by Kittur et al. (2002) on chitin, chitosan and their carboxymethyl derivatives 
(Kittur et al. 2002). The endothermic peak at 108 0C was due to the dehydration of water 
contained in the chitosan polymer  (Ding et al. 2003). Furthermore, the exothermic peak 
at 315 0C was due the degradation of the chitosan main chain due to excess dehydration, 
thermal effects and de-polymerisation (Ding et al. 2003). More importantly, the 
degradation of the amine group (-NH2) in the chitosan backbone was also thought to 
occur at this peak (Asantewaa et al. 2013).  
 
 
Figure	6:	DSC	thermogram	of	pure	chitosan 
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The thermograms for the formulations F1, F3, F5 and F7 were compared to that of pure 
chitosan as shown in Figure 7. This was done to help discern any observable trend with 
each subsequent formulation.  
 
Figure	7:	DSC	thermograms	of	formulations	F1,	F3,	F5	and	F7	with	respect	to	pure	chitosan	
From Figure 7, it can be seen that the samples exhibit an endothermic peak at 
approximately 100 0C which were slightly shifted to the left of the peak manifested in 
pure chitosan sample. Similar to that of unmodified chitosan, the endothermic peaks seen 
in the samples are due to the dehydration of water molecules from –NH2 and –OH groups 
in the chitosan backbone.  
More importantly, it can be seen that the exothermic peaks of the conjugated chitosan 
were progressively shifted to the left with respect to the same exothermic peak produced 
from the pure chitosan. As this peak is correlated to the decomposition of –NH2 groups, 
32		
the reduction in decomposition temperature seen in the conjugates suggest that there was 
a consumption of –NH2 groups brought upon by the N-reductive alkylation reaction with 
increase in boronic acid content. Thus, the shift in decomposition temperature was 
correlated to an increase in degree of substitution. As the aldehyde equivalent was 
increased from F1 to F7, leading to an increased in the degree of substitution, it was 
observed that the decomposition temperature of the conjugates becomes lower with each 
subsequent formulation.  
Along with pure chitosan, the conjugates were also compared with pure 4-FPBA. 
Determination of true melting point of boronic acid and their derivatives has historically 
been documented as difficult to characterise accurately (Hall 2011). Rather than true 
melting points, combustion analysis of boronic acids are more likely reflective of the 
dehydration and decomposition points (Hall 2011; Santucci & Gilman 1958). This is due 
to the inherent water content in the sample which affects the acid-anhydride transition, 
resulting in a range of melting points  (Santucci & Gilman 1958). Figure 8 shows the 
DSC thermogram for pure 4-FPBA.  
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Figure	8:	DSC	thermogram	of	pure	4-formylphenyl	boronic	acid	(4-FPBA) 
 
From figure 8, it can be seen that the 4-FPBA sample for this study was characterised by 
3 peaks with one endothermic peak and two exothermic peaks. The endothermic peak 
seen at 155 0C was primarily due to the dehydration of water molecules from the 4-FPBA 
sample. It was reported that the thermal dehydration of boronic acid leads to the 
formation of anhydride boronic acid known colloquially as boroxines (Hall 2011). Hence, 
the exothermic peak at 299 0C represents the re-solidification of the anhydride derivative 
produced from thermal dehydration while the second exothermic peak at 352 0C 
represents the melting point of this anhydride as previously reported by Santucci & 
Gilman (1958) in a study describing the decomposition of bromine and sulphur 
containing aromatic boronic acid (Santucci & Gilman 1958). It is worth noting that due to 
the facile dehydration of boronic acid, reproducibility of this result with 4-FPBA of 
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different purities is hard to achieve as those samples would have different water content 
and hence, variable heating rates are required to achieve similar results. Water content in 
4-FPBA sample correlates with the purity of the product from the manufacture. In this 
study, 4-FPBA sample with an assay of 95% purity obtained from Sigma Aldrich is used 
for all formulations. This is a major reason most studies report on the melting point of the 
anhydride derivative of the boronic acid  as it is more reliable (Hall 2011). 
Figure 9 show comparisons between 4-FPBA and the conjugates (F1, F3, F5 and F7).  
Figure	9:	DSC	thermograms	of	F1,	F3,	F5	and	F7	with	respect	to	chitosan	and	4-FPBA.	
Note: The formulations are presented as dotted lines and a number specifying the formulation. The 
solid blue line represents the DSC thermogram of chitosan while 4-formylphenylboronic acid(4-
FPBA) is represented by the solid red line 
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As previously noted, the exothermic peak of the conjugates was shifted to the left of the 
peak from pure chitosan. However, in the present comparison, as the degree of 
substitution was increased from F1 to F7, the exothermic peak of the conjugates was 
observed to shift more towards the first exothermic peak of 4-FPBA (to the right). This 
result suggests higher degree of boronic acid substitution favours the formation of the 
anhydrous alternative. 
Comparisons from the DSC thermograms produced by the conjugates reveal that the 
conjugation of 4-FPBA with chitosan resulted in the decomposition of –NH2 in the 
chitosan backbone as well as an increase in the formation of anhydrous boronic acid from 
F1 to F7. Thus, DSC analysis was successful in corroborating the results obtained from 
FTIR analysis as well as indicating that there was a change in physical property and 
consequently, in material organization of the conjugated samples.  
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3.4.4 Enthalpy	Calculations				 
The enthalpy change (DH), is calculated as the area under the exothermic peak in the 
DSC thermogram obtained. As reported by Kittur et al. (2002), an increase in DH of the 
exothermic peak is directly related to the degree of substitution (Kittur et al. 2002). As 
the free unsubstituted amine group is involved directly in Scifff’s base reaction, the DH 
of the exothermic peak in the formulations can be used to ascertain the extent of the 
conjugation between 4-FPBA and chitosan. The DH was calculated through the use of the 
integration by linear function in the TGA Universal Analysis software®. Figure 10 shows 
the enthalpy changes for formulation F1 and F3 whilst Figure 11 shows those for F5 and 
F7. 
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Figure	10:	Enthalpy	calculations	of	formulations	F1	and		F3 
 
Figure	11:	Enthalpy	calculations	of	formulations	F5	and	F7	
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From both figures, it can be seen that the DH values increased from F1 to F3 and again 
from F5 to F7 indicating that the chemical and molecular structure of the formulations 
were modified through the conjugation with 4-FPBA. 4-FPBA is known to be crystalline 
while chitosan is more amorphous so that with an increased level of substitution from F1 
to F7, we should expect an increased level of crystallinity for the conjugates. 
Consequently, more heat was required to facilitate the decomposition of the more 
crystalline formulations which resulted in a higher DH value reported. The effects of 
crystallinity were expanded further in the FESEM (discussed in the next page) analysis 
performed. Thus, this result supports both the findings in the FTIR and DSC analyses and 
confirms the successful bonding of 4-FPBA to chitosan.  
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3.4.5 FESEM	Imaging				 
From the enthalpy analyses, it is expected that the molecular structure of the 4-FPBA 
conjugated chitosan was modified to the more crystalline conformation. The FESEM 
imaging was done to visually illustrate this physical change. Figure 12 shows captured 
SEM images for the formulations F1 to F7. The imaging was done at a magnification of 
1200X at 10.0 kV. 
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Figure	12:	FESEM	images	of	formulations	F1	to	F7 
41		
 
It can be observed from the FESEM images that the conjugates exhibited a more porous 
and spongy looking surface from F1 to F4. As the degrees of substitution in these 
conjugates are relatively low, the SEM images reflected the more amorphous structure of 
chitosan. However, the conjugates started to progressively show a flat hard surface from 
F5 to F7 indicative of a more crystalline structure. As 4-FPBA is inherently crystalline in 
structure, conjugates with high 4-FPBA content should better reflect this crystalline 
nature as observed (Asantewaa et al. 2013).  
Polymer crystallinity are normally determined utilising DSC by quantifying the heat 
associated with the melting and decomposition of the polymer (Blaine 2015). This was 
done in the previous enthalpy analysis whereby there was an increase in DH values from 
F1 to F7 suggesting a more crystalline structure in the later formulations. Thus, these 
FESEM images gives a visual representation of this increased in crystallinity of the 
conjugates and directly corroborates the results obtained from enthalpy analysis. Overall, 
both results strongly suggest that the increased in the degree of substitution in chitosan 
with 4-FPBA led to a more crystalline structure in the conjugates.  
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3.5 	Summary	
The results showed that the conjugation of 4-formylphenylboronic acid (4-FPBA) to 
chitosan was successful and proceed through N-reductive alkylation reaction by utilizing 
the Scifff’s base method. From the FTIR spectra of the conjugates, it was found that the 
boronic acid moiety was bonded to the reactive primary amine site of the chitosan 
backbone. DSC analyses was then performed and the results showed that the material 
organisation of the conjugates was significantly altered by the conjugation. Comparison 
between the DSC thermograms of the conjugates with respect to pure chitosan revealed 
that an increase in the degree of substitution in the conjugates was correlated to the 
consumption of the –NH2 group thereby corroborating the results from FTIR analysis. 
Further comparison of the conjugates shows that the conjugates with high amount of 
boronic acid content tends towards emulating the physical properties of pure 4-FPBA 
more than that of pure chitosan suggesting the physical properties of the conjugates were 
modified through the addition of the boronic acid moieties. 
The change in enthalpy (DH) confirmed that the physical properties of the conjugates 
gradually changes as the degree of substitution increases resulting in a different 
mechanism of chitosan decomposition. FESEM images revealed more insight in the 
physical changes of the conjugates. It was found that conjugates with lower degree of 
substitution showed a more porous and spongy surface similar to that of unmodified 
chitosan. However, conjugates with higher degree of substitution showed a flat surface 
suggesting a more crystalline structure similar to that of 4-FPBA.  
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4.0 FORMULATION	OF	POROUS	AND	NON-POROUS	PLGA	MICROPARTICLES	
4.1 Introduction	
In this chapter we focus on the preparation of porous and non-porous PLGA 
microparticles. In addition, the produced microparticles need to be coated by the boronic 
acid conjugated chitosan in order to impart the glucose sensing capability.  
The general method used in preparing PLGA microparticles includes the creation of oil-
in-water (O/W) and water–in–oil-in-water (W1/O/W2) emulsions by utilizing high speed 
homogenisation and probe tip sonication. As insulin is hydrophilic, the more suitable 
method would be  the water-in-oil-in-water (W1/O/W2) otherwise known as the double 
emulsion method as it has become the more favoured approach for encapsulating 
hydrophilic compounds and protein (Hirenkumar & Siegel 2012). This double emulsion 
process involves first producing the water in oil phase (W/O) by initially dissolving an 
appropriate amount of drug in aqueous phase using deionized water. The aqueous phase 
(W1) is then added to an organic solution (O) containing the PLGA polymer and the 
chosen solvent such as dicholoromethane (DCM), ethyl acetate (EA) or acetone yielding 
the water in oil phase (W1/O). The water in oil primary emulsion is then added to the 
chosen surfactant solution (W2) such as polyvinyl alcohol (PVA) or Polysorbate 80, 
which is then further emulsified at an appropriate stress mixing conditions creating the 
double emulsion phase (W1/O/W2). The organic solvent is then extracted through solvent 
evaporation to yield the microparticle which is then washed thoroughly and freeze dried.  
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Studies show that the choice of solvent, surfactant and stirring rate predominantly affects 
the drug encapsulation efficiency as well as the particle size (Birnbaum et al. 2000). The 
most popular surfactant used for drug loaded PLGA microparticle formation is PVA. 
Emulsification with PVA is known to form particles of relatively small size and uniform 
size distribution (Birnbaum et al. 2000; Sahoo et al. 2002). It is found that residual PVA 
cannot be completely removed from the particles and can be retained at high levels in the 
solution (up to 10% by mass) (Hirenkumar & Siegel 2012; Sahoo et al. 2002). Residual 
PVA is important in maintaining the hydrophilic nature of the microparticles after drying 
to ensure re-suspension of the nanoparticles in aqueous solution (Hirenkumar & Siegel 
2012). In addition, a study by Sahoo et al. (2002) on the effect of residual PVA 
associated with physical and cellular uptake of PLGA nanoparticles observed that 
residual PVA influence the particle size, zeta potential, protein loading as well as the in 
vitro release of the encapsulated drug (Sahoo et al. 2002). Thus, these parameters can be 
easily tuned by altering the PVA concentration in the formulation. These advantages 
afforded by PVA makes it the most suitable choice of surfactant in this study.  
There are a number of approaches reported for formulation of  porous microparticles such 
as parogen leaching method, emulsion/freeze drying and expansion in supercritical fluid 
to name a few (Arayne & Sultana 2006). The porous microparticle produce can vary in 
size depending on the protocols, equipment and reagents used in each experiment. 
Therefore, an important consideration to induce porosity in microparticles must take into 
account the suitability of the method with the aims of the study. A popular method to 
formulate porous microparticles as viable drug carriers is by introducing porosity through 
the use of parogens. These parogens such as ammonium bicarbonate, phosphate buffer 
saline and hydrogen peroxide to name a few, can be incorporated directly into the double 
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emulsion solvent evaporation method to induce porosity (Qutachi et al. 2014). Addition 
of these parogens into the primary aqueous phase (W1) leads to a porous structure during 
rapid polymer precipitation (Luan et al. 2006). Phosphate buffer saline (PBS) was chosen 
in the present study for induction of porosity in the microparticles as it is capable in 
producing consistent pores in PLGA nanoparticles with potential for drug delivery  
(Qutachi et al. 2014). 
The plan is to coat the formed porous and non-porous microparticles with the 4-FPBA 
conjugated chitosan in order to impart the glucose sensing capability. Numerous studies 
suggest that successful coating can be achieved by incorporating the chitosan in the 
second aqueous phase (W2) of the double emulsion solvent evaporation method (Wang, Z 
et al. 2010; Dev et al. 2010; Wang, Y et al. 2013). Utilising this method, chitosan has 
been used to coat unto the surface of the PLGA microparticle through physical adsorption 
(Wang et al. 2013). In this regard, coating is achieved by electrostatic attractive forces 
between the polycationic chitosan and the more negatively charge PLGA particle (Guo & 
Gemeinhart 2008). In the present study, by adding dissolved chitosan into the PVA 
surfactant prior to the formation of the double emulsion we envisage that the chitosan 
would form a coating on the surface and porous structure of the PLGA microparticles 
during the solvent evaporation phase.   
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4.2 Materials	and	Equipment	
Poly (lactic-co-glycolic acid) (PLGA) was obtained from Lakeshore Biomaterials, Poly 
(vinyl alchohol), 87-89% hydrolyzed, and Phosphate buffer saline (PBS) tablets (0.01M 
phosphate buffer, 0.0027M potassium chloride and 0.137M sodium chloride, pH7.4 at 
25°C) was obtained from Sigma-Aldrich. Dichloromethane (DCM) AR grade was 
obtained from Fischer Scientific UK. Sodium hydroxide pellets was obtained from 
Sigma- Aldrich as well. Pure acetic acid purchased from Thermo Fisher Scientific 
(Bridgewater, NJ, USA). 
Equipment used include Perkin Elmer FTIR spectrometer (Spectrum RX1, PerkinElmer 
Ltd, United Kingdom), Field Emission scanning electron microscopy (FESEM) equipped 
with an Energy dispersive x –ray detector (EDX) (Model Quanta 400F, FEI Company, 
USA), high speed homogeniser (IKAT-18, Cole-Palmer, Illinois, USA), Beckman 
Benchtop Centrifuge (Allegra X-22R, Beckman Coulter, Inc., Indianapolis, USA). 
 
4.3 Methods	
4.3.1 General	protocols	for	formulation	of	porous	and	non-porous	PLGA	
microparticles	
The protocol was based upon the double solvent evaporation method, with an additional 
step involving the addition of 4-FPBA conjugated chitosan into the formulation. 
100 mg of PLGA was dissolved in 5 ml of dichloromethane (DCM) in 50 ml beaker 
producing 2% w/v of PLGA solution (oil phase). The beaker was placed on the orbital 
shaker set to 30 rpm for 10 minutes to ensure the PLGA is fully dissolved. For 
formulations with induced porosity, 250 µl of PBS solution (W1 phase) was added to the 
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PLGA/DCM solution and homogenised using high speed homogeniser at 9000 rpm for 2 
minutes to create the primary emulsion (W1/O). However, for non-porous formulations, 
100 µl of distilled water was added into the PLGA/DCM solution in place of PBS. Time 
and speed of the homogeniser was identical to the porous formulations.   
The dissolved conjugated chitosan (1% acetic acid) was poured into a 400 ml beaker 
containing 200 ml of 0.3% w/v PVA solution (W2). The solution was gently stirred using 
a magnetic stirrer at speed 300 rpm for 30 min to ensure homogeneity. Next, the primary 
emulsion (W1/O) was added to the PVA-chitosan solution to form the secondary 
emulsion (W1/O/W2) and homogenised at 6000 rpm for 2 minutes. The secondary 
emulsion was then stirred at 300 rpm under a fume cupboard for 4 hours to allow for 
solvent evaporation and particle hardening.  
The solution was then poured into separate 50 ml centrifuge tubes and was centrifuged at 
4500 rpm for 15 minutes. The non-porous formulations were then collected and washed 
with distilled and subjected to centrifugation in a similar manner. This washing cycle was 
repeated thrice to ensure residual solvent was eliminated from the particles. For the 
porous formulations, the particles were collected and stored for further treatment to 
enhance pore formation before undergoing the same washing cycle. Both formulations 
were then air dried by storing in a room temperature environment overnight. The 
formulations were stored at 4 0C dry air refrigerator for a maximum period of one week 
prior to characterisation. As the physical integrity of PLGA microparticles is affected by 
the storage temperature, duration of storage and size of the particles, the short storage 
time for the formulations prior to analysis was done to avoid significant aggregation that 
may influence characterisation of these samples (De & Robinson 2004). Both 
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formulations were done for each experimental run until the optimum protocols were 
established for characterisation analysis.  
4.3.2 Protocols	to	enhance	porosity	of	particles		
In the porous formulations, the collected particles were exposed to ethanolic –NaOH to 
enhance surface porosity. The ethanolic-NaOH was prepared by mixing 1.0M NaOH and 
96% ethanol at a ratio of 30:70. 10 ml aliquot of ethanolic-NaOH was then added rapidly 
to a 50 ml centrifuge tube containing the sample whilst on a vortex mixer and was 
vortexed at 1400 rpm for 7 minutes. The sample was then centrifuged and the excess 
ethanolic-NaOH was discarded before proceeding to a similar washing cycle as the non-
porous formulation. Different concentrations of NaOH ranging from 0.5M to 0.8M were 
evaluated in order to optimise the best condition for imparting porosity on the sample.  
 
4.3.3 Characterisation of PLGA microparticles by FESEM analysis 
FESEM imaging was performed to identify the surface characteristics and size of the 
sample.  A small amount of the dried sample was placed unto an FESEM imaging stub. 
The sample was then viewed under field-emission FESEM at 5.0 kV.  
 
4.3.4 Porosity	Calculations		
The porosity of the microparticles was calculated using equation 2,  
 !"#"$%&'	% = 1 − -.//.#01&-!234 ×	100  ……………………………………………… (2) 
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The theoretical density of PLGA polymer (rPLGA ) was taken from literature as 1.3 g/cm3 
(Polysciences 2016). The apparent density (rapparent) of the PLGA microparticles was 
calculated based upon the displacement method. Briefly, 5 ml of distilled water at room 
temperature was poured into a 10 ml graded measuring cylinder and the initial volume 
was recorded. While tilting the measuring cylinder, a recorded amount of PLGA 
microsphere sample was placed into the cylinder. The final water level was then recorded 
and the amount of water displaced by the sample represents the apparent volume of the 
sample. As distilled water was used at room temperature, 1 ml of volume displaced 
represent 1 cm3 of the volume of sample. The apparent density can then be calculated 
from equation 3. All measurements were done in triplicates. A simple two-tailed t-test 
was performed with 95% confidence interval to check for significant differences between 
experimental results where necessary. 
 !"##"$%&' =	 *+,,-./012  …………………………………………………...………… (3) 
 
4.3.5 Fourier	transform	infra-red	analysis	(FTIR)	
 FTIR analysis was needed to ascertain whether the conjugated chitosan was successfully 
coated unto the PLGA microparticle and to complement data from the DCS analyses. A 
small amount of the lyophilised sample was crushed gently with approximately 250 mg 
of KBr powder until homogeneous powder is obtained. The powder was then compressed 
under 6 tonnes of pressure (5000 psi) using a pneumatic table press to form a disc. The 
spectra were collected at the range of 4000- 400 cm-1 with measurements done in 
triplicates for each sample.  
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4.4 Results	and	Discussion	
4.4.1 Formulation	of	non-porous	PLGA	microparticles	
Utilising the double emulsion solvent evaporation method, the non-porous PLGA 
microparticles were successfully formulated. Figure 13 shows the FESEM images of the 
non-porous formulation. The image was taken at 5.0 kV at 2500 x and 500 x 
magnification respectively.  
 
 
Figure	13:	FESEM	images	of	non-porous	PLGA	microparticles	with	A	representing	the	FESEM	image	
taken	at	2500	X	magnification	and		B	at	500	X	magnification.	
 
From the FESEM image A in Figure 13, it can be seen that the non-porous formulation 
produced sub-micron PLGA particles that were non-porous as well, spherical in shape 
with relatively uniform size ranging from 1.0 µm to 10 µm. As the particles are sub-
micron, particle size analyser specifically the Zetasizer Nano instrument was not suitable 
for calculating the mean particle size. However, it can be seen from the representative 
sample in figure 13 that the relative uniform size of the particles obtained demonstrate the 
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viability of the protocols used to formulate consistent non-porous PLGA microparticles 
and is adequate to fulfil the objectives of this study.  
The stirring rate of the secondary emulsion plays a significant role in the particle size of 
the formulation as reported in a previous study on optimisation techniques for the 
formulation of PLGA microspheres (Birnbaum et al. 2000). The stirring rate used in the 
present study was set to 6000 rpm which was much higher than those reported in several 
microsphere formulation investigations and we believe this is the cause of the submicron 
sized particle production. Thus, nano-size PLGA particles can be achieved through the 
double emulsion method by gradually increasing the stirring rate of the secondary 
emulsion or by increasing the concentration of PVA surfactant. However, as the objective 
of the present study was to investigate the effects of porosity on the glucose sensitivity 
and insulin release from PLGA microparticles, the range of particle sizes obtained in this 
formulation were nonetheless adequate to carry out the objectives of this study. 
Furthermore, the non-porous formulation showed very little aggregation as seen in the 
FESEM image B of Figure 13. This is due to the use of partially hydrolysed PVA (87%-
89%) as opposed to fully hydrolysed PVA in the secondary aqueous phase. The degree of 
hydrolysis of the PVA plays a significant role in the aggregation of PLGA microparticles. 
As the degree of hydrolysis increases, the hydrophilicity of the PVA decreases which 
increases the hydrogen bonds between intra- and inter PVA molecules rather than with 
water molecule. The formation of these hydrogen bonds hinders the hydrophobic portions 
of the PVA to be absorbed to the surface of the PLGA particle which would result in 
unstable dispersion and agglomeration (Murakami et al. 1997). Murakami et. al (1997) 
found that by utilising PVA with high degree of hydrolysation (up to 98.5%) produced 
aggregated nanoparticles, leading to a decrease in the yield observed (Murakami et al. 
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1997). This was attributed primarily due to the increase in PVA-PVA hydrogen bonds 
leading to unstable nanoparticles. By using partially hydrolysed PVA, the PVA molecule 
was unhindered and can successfully be absorbed to the surface of the PLGA particle. In 
addition, the large amount of PVA solution used to emulsify the primary emulsion 
provides a large continuous phase for the precipitation of stable sub-micron particles. 
Both factors decreased the chances of aggregation and produced the stable PLGA 
microparticles seen in the figure.  
 
4.4.2 Optimisation	of	porous	PLGA	microparticle	
The protocol outlined in section 4.3.1 was used to formulate the porous PLGA 
microparticles. After centrifugation, the particles were exposed to ethanolic-NaOH to 
enhance the porosity within the particles as described by Qutachi et al. (2014) on their 
injectable PLGA microspheres (Qutachi et al. 2014). Their study describes the suitability 
of ethanolic –NaOH in producing uniform pores in PLGA microparticles since ethanol is 
a water- miscible solvent capable of partially dissolving PLGA while NaOH improves the 
polyester wettability by promoting the carboxylic acid exposure on the polymer surface 
making it more hydrophilic (Qutachi et al. 2014). This in effect causes the opening of the 
pores present on the surface of the particle resulting in a tangible increase in the overall 
porosity of the particle.   
Figure 14 shows the FESEM images of the porous formulation after treatment with 
ethanolic –NaOH mixture at 1.0M NaOH. The images were taken at 5.0 kV at 2500 X 
and 500 X magnification. 
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The FESEM image (A) in Figure 14 shows that upon addition of the ethanolic- NaOH, 
most of the PLGA microparticles were ruptured and failed to retain its spherical shape.  
Fragments of the PLGA particle were seen to be clumped to together forming large 
aggregate sections. Agglomeration was so severe throughout the sample shown in 
FESEM image B that discrete PLGA microparticles were hard to discern. While it was 
observed that in some of the particles there was evidence of pore formation, the particles 
were unstable and deemed unsuitable for drug loading applications. Therefore, this high 
strength of NaOH may not be suitable for imparting the required level of porosity without 
harming the integrity of the microparticles. 
Further optimizations were to be carried out in order to strike the right balance for pore 
formation. The formulations studied are shown in Table 3 in which the concentration of 
sodium hydroxide was gradually decreased from 1.0M to 0.5M. Other factors such as the 
ratio of PLGA to chitosan as well as the speed and duration of the vortex mixer were kept 
constant.  
Figure	14:	FESEM	images	of	porous	PLGA	microparticles	with	A	representing	the	FESEM	image	
taken	at	2500	X	magnification	and	B	at	500	X	magnification 
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											Table	3:	Optimisation	of	formulation	for	porosity	of	PLGA	microparticles	
 
Formulation 
 
PLGA (mg) 
 
Chitosan (mg) 
Conc. NaOH in 
Ethanolic-NaOH 
mixture 
F1 100 35 0.80 M 
F2 100 35 0.70 M 
F3 100 35 0.60 M  
F4 100 35 0.54 M 
F5 100 35 0.52 M 
F6 100 35 0.51 M 
F7 100 35 0.50 M 
 
A report by Guo & Gemeinhart (2008) showed that as more chitosan was added into the 
PLGA nanoparticles, the size grew larger suggesting that the chitosan continually coats 
the surface of the particles in multiple layers (Guo & Gemeinhart 2008). Thus, by 
controlling the ratio of PLGA to chitosan in each formulation, the amount of chitosan 
incorporated can be regulated for each formulation. In order to accurately investigate the 
effects of the concentration of sodium hydroxide on the porosity observed, the amount of 
ethanolic- NaOH as well as exposure time were kept constant at the values set in the 
protocols described in 4.3.2.  
The FESEM images of formulations F1 –F4 are shown in the Figure 15 and those for F5-
F7 in Figure 16. The images were taken at 5.0 kV at 2500X magnification. 
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Figure	15:	The	FESEM	images	of	porous	formulations	F1	to	F4	at	2500X	magnification 
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		Figure	16:	The	SEM	images	for	porous	formulations	F5	to	F7	at	2500X	magnification	
From both figures, we observed a gradual change in the microstructure of the PLGA 
microparticles as the NaOH concentration in the ethanolic –NaOH mixture was 
decreased. At NaOH concentration of 0.80M to 0.54M (F1 to F4, Figure 15), exposure to 
ethanolic-NaOH resulted in the formulation having a similar but less severe 
fragmentation and agglomeration than those noted in the 1.0M NaOH formulation. 
However, as the concentration of NaOH was decreased below 0.54M, less fragmentation 
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of the PLGA particle was observed and the sub- micron particles formed were relatively 
stable. Concurrently, we can claim that the pores appear to decrease with decreased 
NaOH concentration. At NaOH concentration of 0.52M and 0.51M (formulations F5 and 
F6 shown in Figure 16), the PLGA microparticles retained their spherical shape with less 
agglomeration. Pores on the surface of the microparticles were also visible on the 
FESEM images in these formulations. Finally, at 0.50M NaOH, the formulation (F7) 
showed no porosity on the surface and the microparticles formed were discrete and stable 
which suggest that exposure of the microparticles to this concentration of NaOH in the 
the ethanolic- NaOH was inadequate to induce porosity on the surface of the particle 
without destroying the integrity of the particles. From this optimisation study, F6 
presented the most desirable characteristics in terms of the nature of the pores 
discreteness fragmentation. Hence, F6 was used for subsequent investigations. 
 
4.4.3 Porosity	Calculations		
Porosity calculation was done in order to quantify the degree of porosity within the 
microparticles in the porous and non-porous PLGA microparticles. In order to calculate 
porosity, the apparent density of the sample must be determined beforehand. The 
apparent density is defined as the mass per unit volume of the material, including the 
voids which are inherent in the material (Webb 2001). The apparent density was 
calculated based upon the displacement method.  
Table 4 compares the porosity values with standard error in both porous and non-porous 
PLGA microparticle samples. All measurements were done in triplicates.  
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Table	4:	Porosity	values	for	non-porous	and	porous	PLGA	microparticles	formulations	
Sample F1 (Non-porous PLGA MP) F2 (Porous PLGA MP) 
Mass Recorded (mg) 250  250 
Apparent Volume (cm3) 0.20 ± 0.10 0.57 ± 0.03 
Apparent Density (g/ cm3) 1.25±0.01 0.44 ± 0.02 
Theoretical Density (g/ cm3) 1.30 1.30 
Porosity % 3.88 ± 0.02 64.07 ± 1.74 
 
An independent two sample t-test was conducted to compare the apparent density and 
porosity between the two formulations. With reference to Table 4, it can be seen that the 
apparent density of the porous PLGA microparticle formulation (M= 0.44 g/cm3, SD = 
0.03 g/cm3) is lower than that of the non-porous sample (M= 1.25 g/cm3, SD = 0.02 
g/cm3) owing to the increase in voids and pockets associated with porous microparticle as 
observed in the SEM images in Figure 16; t(3)= 3.18, p < 0.05. A decrease in apparent 
density in the PLGA microparticle sample correlates to higher porosity value as seen in 
the table. Overall, the porous PLGA microparticle showed a high porosity value (M= 
64.07%, SD = 3.01%) as compared to the non-porous sample (M= 3.88%, SD= 0.03%); 
t(3)= 3.58, p < 0.05. This represents the maximum achievable porosity without 
compromising the structural integrity of the PLGA microparticles for the current 
protocols used in this study. The reported porosity is in line with other studies regarding 
injectable porous PLGA microspheres with porosity ranging from 66 to 74% showing 
measurable characteristic differences including drug release kinetics as compared to non-
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porous variants (Qutachi et al. 2014). Thus, incorporating a parogen during the double 
solvent evaporation process as well as the additional exposure of the samples to ethanolic 
– NaOH provided a reproducible pathway to formulate porous PLGA microparticles.  
 
4.4.4 FTIR	analyses	on	chitosan	incorporated	PLGA	microparticles	
One of the objectives of the present study was to produce PLGA microparticles coated 
with 4-FPBA conjugated chitosan in order to impart the glucose specificity on the insulin 
loaded PLGA microparticle. With the successful formulation of the non-porous and 
porous PLGA microparticles, an investigation was conducted to ascertain whether the 4-
FPBA–conjugated chitosan was successfully incorporated into the PLGA microparticles.  
Comparisons between uncoated PLGA microparticle (Pure PLGA MP) and chitosan-
coated formulations (PLGA MP F1 and PLGA MP F2) were required to accurately 
perform this investigation. The formulations were based on the protocol for the non-
porous microparticles detailed in section 4.3.1. 4-FPBA conjugated chitosan with a high 
degree of substitution (aldehyde equivalent of 16) was used to coat the non-porous PLGA 
microparticle for ease of analysis. Table 5 shows the formulations used for FTIR 
analysis. 
 
Table	5:	Formulations	for	chitosan	coated	PLGA	microparticles	studies	
Formulation PLGA (mg) Conjugated 
Chitosan (mg) 
Ratio PLGA: 
Chitosan 
Pure PLGA MP 100 0 1: 0 
PLGA MP F1 100 35 1: 0.35 
PLGA MP F2 100 70 1: 0.70 
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Figure 17 shows the FTIR spectra obtained from the PLGA microparticles formulated for 
this investigation. The spectra were collected at a range of 4000- 400 cm-1. The 
formulations were then compared to the FTIR spectra of pure chitosan.  
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Figure	17:	FTIR	spectra	of	chitosan	coated	formulations	with	respect	to	uncoated	PLGA	microparticles	(MP),	pure	
unmodified	chitosan	and	4-FPBA-chitosan	conjugates 
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With reference to Figure 17, pure chitosan is shown to have an intense peak at 1650 cm-1 
confirming the presence of the primary amine (–NH2) group in the chemical structure of 
chitosan (Ding et al. 2003). Note, the peak at 1650 cm-1 was deemphasized after N-
reductive alkylation reaction in which 4-FPBA was conjugated to chitosan as shown in 
the figure. Furthermore, C-H bond stretching was characterised as the peak in 2900 cm-1 
while C-H bend peak is shown in the range 1360 -1440 cm-1. Finally, N-H bond 
stretching was shown as a wide peak at 3500 cm-1.  
In the uncoated (pure) PLGA microparticles FTIR spectra, the peak observed at 1088 cm-
1 is due to the C-O-C stretching while C-H stretching of the methyl group is characterised 
by the peak at 1460 cm-1 (Wang et al. 2013). Other characteristic peaks of PLGA are 
between 2850 cm-1 and 3000 cm-1 are due to CH, CH2 and CH3 stretching vibration. 
Lastly, the peak at 3500 cm-1 is due to OH stretching which overlapped the N-H bond 
stretching peak in pure chitosan sample.   
It can be seen that the chitosan peak associated with N-H stretching was also present in 
the FTIR spectra of the chitosan coated PLGA microparticle formulations. As the peaks 
in the uncoated PLGA microparticles and pure chitosan overlaps at 3500 cm-1, the 
inclusion of chitosan in the formulation manifested an increase in the intensity of this 
peak as seen in F1. In addition, by doubling the ratio of PLGA: chitosan as in in F2 with 
respect to F1, the intensity of this peak was increased further. This result suggests that as 
the ratio of PLGA: chitosan was increased in the formulation, more of the chitosan was 
adsorbed on the surface of the PLGA particle. This observation is supported by a similar 
data reported by Guo & Gemeinhart (2008) on the adsorption mechanism of chitosan 
unto the surface of PLGA particles whereby the researchers postulate that as the amount 
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of chitosan was increased in the PLGA nanoparticle formulations, multiple layers of 
chitosan was formed on the surface of the PLGA nanoparticle (Guo & Gemeinhart 2008).  
Further analyses showed that another chitosan peak at 1650 cm-1 was present in the 
chitosan coated PLGA microparticle formulations suggesting that the free amine group (-
NH2) expressed in the chitosan backbone was also present in the microparticle 
formulations.  Similarly, it was observed that the sharpness of this peak increased when 
the ratio of PLGA: chitosan was doubled as in F2 with respect to F1. More importantly, it 
can be seen that peaks at 1515 – 1560 cm-1 characterised previously in 4-FPBA 
conjugated chitosan were present in F1 which resolves into greater detail in F2. Thus, 
through this procedure, we can confirm that the 4-FPBA conjugated chitosan was 
successfully incorporated within the PLGA microparticles.  
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 4.5 	Summary	
The double solvent evaporation method was used to formulate both non-porous and 
porous chitosan coated PLGA microparticle. Utilising this method, the non-porous 
formulation showed spherical microparticles of relatively uniform sizes in the range of 
1.0 to 10.0 µm with no agglomeration. However, optimisation was required in order to 
formulate porous microparticles with desirable porosity and pore characteristics. The use 
of concentrated NaOH (1 M) in ethanolic-NaOH mixture to enhance porosity resulted in 
the rupture of most of the nanoparticles. This fragmentation then resulted in significant 
agglomeration which makes characterization of the particles difficult. By decreasing the 
concentration of NaOH to 0.515M, exposure to ethanolic-NaOH mixture resulted in 
porous PLGA microparticles of similar sizes to that of the non-porous formulation. The 
porous particles formed were spherical, stable with numerous pores observed on the 
surface. 
Through FTIR analyses, it was confirmed that modified chitosan was successfully 
incorporated in the PLGA microparticles with certain chitosan peaks present in the FTIR 
spectra of the PLGA microparticle formulations. Thus, the modified protocols that were 
added into the double solvent evaporation method to incorporate 4-FPBA conjugated 
chitosan is viable in producing coated PLGA microparticles.  
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5.0 GLUCOSE	ABSORPTION	BY	PLGA	MICROPARTICLES	
5.1 Introduction	
This chapter focusses on the glucose absorption propensities of both porous and non-
porous PLGA microparticles. With the successful formulation of 4-FPBA modified 
chitosan- coated PLGA microparticles, we moved to the next objective of the study 
which is to evaluate the extent of the glucose absorption on the two types of 
microparticles (porous and non-porous). Matsumoto et al. (2002) managed to formulate 
chitosan gel that had been modified by phenylboronate for selective absorption of glucose 
(Matsumoto et al. 2002). To ascertain the adsorption capacity and selectivity of the 
modified chitosan gel compared to those of the commercial gel, the team used glucose 
and 1-methyl-a-D-glucoside as adsorbates. Phenylboronate anion is known to form 
complexes with cis-1,2 or 1,3 diols which are both present in glucose (Matsumoto et al. 
2002). The study by Matsumoto et al. (2002) concluded that the phenylboronate chitosan 
gel provided a higher absorption of glucose compared to 1-methyl-a-D-glucoside. Thus, 
boronic acid and their derivatives was proven to be sensitive towards glucose based on 
the findings of Matsumoto et al. (2002) as well as numerous other studies regarding 
glucose sensitive boronic acid materials (Matsumoto et al. 2002; Jennifer N. Cambre & 
Sumerlin 2011). However, it was found that it is difficult to directly characterised glucose 
via UV- spectroscopy and indirect methods are required to accurately determine the 
absorbance of glucose in this study. 
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One method of indirectly measuring the absorbance of glucose involves the use of 
glucose hexokinase reagent (Galant et al. 2015). The reaction involves glucose being 
converted to glucose-6-phosphate and nicotinamide adenine dinucleotide (NAD+) in the 
presence of enzyme hexokinase (HK). Glucose-6-phosphate by-product is then oxidised 
to 6-phosphogluconate by glucose-6-phosphate dehydrogenase while nicotinamide 
adenine dinucleotide (NAD+) is reduced to NADH. NADH can then be detected by UV-
spectroscopy at 340 nm. The overall reaction is shown in figure 18.  
 
Figure	18:	Overall	conversion	of	glucose	to	detectable	NADH	by	reaction	with	hexokinase	reagent	
 
Another method of indirectly measuring glucose absorbance is by utilising curcumin to 
directly detect boronic acid derivatives. Curcumin has been used to detect boronic acid 
and their derivatives in previous studies due to ease of analysis with UV-spectroscopy 
(Lawrence et al. 2012; Siddiqui et al. 2017). Curcumin reacts readily with boronic acid to 
form a complex (rosocyanine) and can be easily detectable at a wavelength of 425 nm. 
Furthermore, the complex rosocyanine shown in Figure 19 forms a solution of bright red 
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in colour (Lawrence et al. 2012). The characteristic colour change from yellow 
(curcumin) to red on formation of the complex can also be used as a visual indicator for 
the presence of boronic acid derivatives. 
 
 
Figure	19:	Chemical	structure	of	rosocyanine	complex	
 
The two indirect methods discussed are viable methods to investigate the glucose 
absorption propensity of the microparticles. However, the more suitable method used in 
the present study was by curcumin reaction with 4-FPBA content in the chitosan coated 
PLGA microparticles in an HPLC analysis. This provided an efficient and easier analyses 
as well as providing visual feedback through the colour change brought upon by the 
rosocyanine complex. Figure 20 shows the overall reaction of the 4-FPBA-chitosan 
coated PLGA microparticle with curcumin. By determining the amount of 4-FPBA in 
both porous and non-porous formulations of PLGA microparticles, the difference in 
absorbance of curcumin between the two formulations would give an indirect indication 
of the sensitivity of the PLGA microparticles towards glucose.  
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Figure	20:	Overall	reaction	between	4-FPBA	modified	chitosan	coated	PLGA	microparticles	and	
curcumin	
69		
Materials and Equipment 
HPLC grade acetonitrile and methanol obtained from Thermo Fischer Scientific (New 
Jersey, USA), pure acetic and curcumin purchased from Thermo Fisher Scientific 
(Bridgewater, NJ, USA). Poly (lactic-co-glycolic acid) (PLGA) was obtained from 
Lakeshore Biomaterials, low molecular weight chitosan was purchased from Sigma 
Aldrich (St.Louis,MO, USA); 4-formylphenylboronic acid (4-FPBA) and sodium 
borohydride was purchased from Thermo Fisher Scientific (Bridgewater, NJ, USA). Type 
one ultrapure Milli-QÒ Water (18.2 ohms at 250C) obtained from Merck Sdn. Bhd. 
(Selangor, Malaysia).  
 
Equipment used include HPLC (Perkin Elmer, Shelton, Connectticut, USA), HPLC 
column with the specification of Agilent Zorbax 300SB-4.6 x 250 mm C18, with particle 
size of 5 µm and pore size of 300 Å (Agilent Technologies, California, USA), Beckman 
Coulter Microfuge 16 centrifuge (Beckman Coulter, Inc., Indianapolis, USA). 
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5.2 Method	
5.2.1 	HPLC	analysis	for	glucose	adsorption	
The HPLC solvent system comprised of acetonitrile as solvent A, 0.01 % acetic acid as 
solvent B and methanol as solvent C in the ratio 53:42:5. The flowrate was set to 1.5 
ml/min with isocratic elution. The detection wavelength was set to 425 nm with an 
injection volume of 10µl. Elution was through an Agilent Zorbax 300SB-4.6 x 250 mm 
C18, with particle size of 5 µm and pore size of 300 Å. 
The calibration curve was constructed from curcumin solution dissolved in methanol 
ranging from 0-50 µg/ml. A calibration curve of average peak height against curcumin 
concentration was then constructed and the coefficient of determination (R2) and equation 
of the line were determined. Preparation of sample involved measuring 10 mg of each 
sample into a micro-centrifuge tube. The sample was then exposed to 1 ml of mili-Q 
water before addition of 500 µl of 0.1 mg/ml of curcumin solution. To calculate the 
absorbance of free curcumin, the mixture was centrifuged at 14000 rpm for 2 minutes and 
10 µl of the supernatant was injected into the HPLC system. Samples were run in 
triplicates. 
 
5.2.2 	Yield	analysis	of	the	4-FPBA	conjugated	chitosan	PLGA	
microparticles	
The yield was calculated to observe any quantifiable differences in 4-FPBA content due 
to the porosity of the chitosan incorporated PLGA microparticles. The initial weight was 
based upon the total weight of PLGA and modified chitosan used in the formulation of 
PLGA microparticles. 
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Briefly, after formulation of both porous and non-porous PLGA microparticles as 
documented in section 4.3.1 and 4.3.2, the samples were freeze dried for up to 48 hours 
to ensure all moisture was eliminated. The recorded weigh of the dry samples was then 
compared to the initial weight and yield. Yield analysis was done on three separate 
batches of formulations in order to get an average yield for the samples.  
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5.3 Results	and	Discussion	
5.3.1 HPLC	analysis	of	curcumin	
The HPLC system was set to detect curcumin at a wavelength of 425 nm. Figure 21 
shows the chromatogram of curcumin standard solution of 50 µg/ml after a sample run of 
5 minutes. It can be seen that there is one clearly resolved peak representing the curcumin 
peak at an elution time of approximately 2.3 minutes.  
 
 
 
 
 	
 
 
 
 
 
The calibration curve was constructed from curcumin standard solution range of 50 to 0 
µg/ml.  Figure 22 shows the calibration curve of curcumin standard solution. The 
calibration curve was constructed by plotting the peak height with curcumin 
concentration. It can be seen from the figure that the peak height was proportional to the 
Figure	21:	Chromatogram	of	curcumin	standard	solution	50	µg/ml 
73		
curcumin concentration which gave the standard curve a good linearity reflected by the 
coefficient of determination (R2) value of 0.999.  
 
Figure	22:	Calibration	curve	for	curcumin	standard	solution	0	–	50	µg/ml	
 
Limit of detection (LOD) and limit of quantitation (LOQ) was also determined by 
utilising the calibration curve in figure 22. In general, LOD represents the lowest 
concentration of an analyte in a sample that can be detected, but not necessarily 
quantified under the stated conditions of the study (Shrivastava & Gupta 2011). On the 
other hand, the LOQ is defined as the lowest concentration of an analyte in a sample that 
can be determined with acceptable precision and accuracy under the stated conditions of 
the test (Shrivastava & Gupta 2011). As the HPLC system was calibrated to eliminate 
baseline noise as observed in figure 21, the linear regression method was used to 
determine both LOD and LOQ as it is the most applicable method that does not involve 
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background noise and is most effective for range of low values close to zero for the 
calibration curve (Shrivastava & Gupta 2011). For a linear calibration curve, it is 
assumed that the instrument response y is linearly related to the standard concentration x 
for a limited range of concentration. This is the underlying assumption in constructing the 
calibration curve in figure 22. This linear regression model can be used to compute both 
LOD and LOQ respectively using the following equations (Shrivastava & Gupta 2011). 
 !"# = 	 &'() 	  ………………....(4) 
 !"# = 	 &'()* 		  ……………….(5) 
 
where  
Sa is the standard deviation of the y-residuals of the regression line.  
b is the slope of the calibration curve 
 
By utilising the LINEST function in Microsoft Excel software® to calculate the standard 
deviation of the y-residuals of the regression line (2.70), the calculated values of LOD 
and LOQ utilising equations 4 and 5 are 0.69 µg/ml and 2.32 µg/ml respectively. As the 
lowest concentration used to construct the calibration curve (3.12 µg/ml) is higher than 
both LOD and LOQ concentrations, the HPLC system used in this study is deemed fit for 
purpose and subsequent curcumin concentrations can be reliably and accurately 
determined using the aforementioned calibration curve. 
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As discussed previously, 4-FPBA reacts with curcumin forming a rosocyanine complex 
mixture. Initially, the curcumin concentration that was added into the samples was set to 
0.1 mg/ml. By measuring the free curcumin that is unreacted in the final mixture, 
comparisons can be made between the amount of 4-FPBA in the chitosan coated PLGA 
microparticle in the porous and non-porous samples. The concentration of free curcumin 
was determined from the standard curve obtained in Figure 22, which was then used to 
calculate the percentage of curcumin consumed by the samples utilising equation 6.  
 
 !"#$"%&'	$)'*"%+,	%= 	 (0&'12	$"#$"%&'	$)'$+'3#13&)'-5'&3&12	$"#$"%&'	$)'$+'3#13&)')5'&3&12	$"#$"%&'	$)'$+'3#13&)' 	×	100  
                 ……….(6)  
 
 
Figure 23 shows the percentage of curcumin consumed by the non–porous PLGA 
microparticle sample (F1) and the porous PLGA microparticle sample (F2). 
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Figure	23:	Curcumin	consumption	(%)	of	non-porous	and	porous	PLGA	microparticles,	n=3	
 
It can be seen that the percentage of curcumin consumed from the porous chitosan coated 
PLGA microparticles (F2) was notably higher than that of the non-porous sample (F1). 
This result showed definitively that the amount of 4-FPBA content was inherently higher 
in the porous microparticle sample which caused the increased in curcumin consumed in 
the reaction.  
It was observed that an approximately 5% increase in the percentage of curcumin 
consumed for F2 was due to the highly porous structure of the PLGA microparticle. We 
may conclude that the porous structure afforded by the PLGA microparticle leads to an 
increase in surface area available for coating (Ilyas et al. 2013). Thus, more of the 
modified chitosan with 4-FPBA was able to coat upon the surface of the PLGA 
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microparticle and was more readily available to react with curcumin. In comparison, the 
non-porous PLGA microparticle sample provided less surface area for chitosan to be 
coated onto leading to a decrease in the amount of 4-FPBA available for reaction with 
curcumin. As 4-FPBA is documented to be sensitive to glucose, it can be said that the 
porous chitosan coated PLGA microparticle sample (F2) is likely to provide a better 
overall sensitivity characteristic towards glucose as compared to the non- porous sample.  
In addition to HPLC measurement, the formation of rosocyanine leads to a change in 
colour of the mixture. The intensity of the colour change between the samples F1 and F2 
gives a visual comparison of the concentration of 4-FPBA in each sample. Figure 24 
shows the colour change for sample F1 and F2 after addition of curcumin, note the initial 
colour of curcumin was bright yellow in standard solution. 
 
 
Figure	24:	Color	change	exhibited	by	non-porous	PLGA	microparticle	(F1)	and	porous	PLGA	
microparticles	(F2)	upon	reaction	with	curcumin	
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It was observed that the colour change of sample F2 was more intense than F1 in Figure 
24 with the mixture changing colour from initial bright yellow to orange. The colour 
change of F1 was less discernible suggesting significantly lesser amount of the 
rosocyanine complex formed in the mixture. This visual comparison corroborates the 
results obtained from the HPLC analysis whereby the amount of 4-FPBA available for 
reaction with curcumin to form the rosocyanine complex was notably higher in the 
porous PLGA microparticle owing to the increased in surface area available for chitosan 
coating.  
 
5.3.2 Yield	analyses		
Yield analyses was performed in order to further quantify and compare the difference in 
4-FPBA content available for curcumin detection in porous and non-porous PLGA 
microparticle samples. Yield was calculated based on the initial weight of materials 
added into the formulation. Both samples consist of 100 mg of PLGA and 35 mg of 4-
FPBA modified chitosan as per the PLGA: chitosan ratio of 1: 0.35. The lyophilised 
samples were measured as the final dry weight of the microparticles and assumed to have 
negligible moisture content. The yield was then calculated based on equation 7 and all 
values are tabulated in Table 6.   
 !"#$%	% = 	 (*"+,$	%-.	/#"0ℎ2-4+"2",$	/#"0ℎ2)4+"2",$	/#"0ℎ2 	×	100  ………… (7) 
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Table	6:	Yield	of	4-FPBA	in	non-porous	and	porous	PLGA	microparticles	formulations	
Sample F1 (Non-porous PLGA MP) F2 (Porous PLGA MP) 
Initial weight (mg) 135  135 
Dry weight (mg) 65.0 ± 2.38 83.9 ± 2.29 
Yield % 48.2 ± 1.76 62.1 ± 1.69 
 
 
The yield for porous PLGA microparticle sample was observed to be higher (62.1%) than 
the non-porous PLGA microparticle sample (48.2%) as seen in Table 6. This results 
postulates that the highly porous structure in F2 resulted in an increased in surface area 
available for coating. Thus, the increase in available surface area afforded by the more 
porous network within the microparticles caused more of the modified chitosan to be 
retained in the formulation resulting in a higher yield percentage. In contrast, the limited 
surface area available for incorporation by the non-porous microparticles (F1) resulted in 
less of the modified chitosan to be incorporated in the final formulation showing a lower 
yield percentage. This result corroborates the findings in the curcumin analyses whereby 
the amount of curcumin consumed by the porous PLGA microparticles was higher than 
in the non-porous sample which gives an indication that the amount of detectable 4-
FPBA was higher in the porous microparticle sample. The yield calculated here gives a 
more accurate quantification on the amount of 4-FPBA available present in the 
microparticles for curcumin detection. Thus, with both results, we can say that the highly 
porous structure of the PLGA microparticle was able to incorporate more of the modified 
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chitosan and consequently, a higher detectable 4-FPBA content as well as provide a 
larger effective surface area for curcumin – 4-FPBA interaction to facilitate the higher 
glucose absorption characteristic observed.  
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5.4 Summary		
The glucose absorption of the PLGA microparticle samples was successfully ascertained 
through an indirect method of utilising curcumin to detect 4-FPBA content in the 
microparticle sample. By comparing the curcumin concentration before and after reaction 
with PLGA microparticles, the percentage of curcumin consumed by the boronic acid 
moieties within the microparticles was determined.  
From the HPLC analyses, it was found that the porous PLGA microparticles consumed 
more curcumin compared to the non-porous sample. The increase in surface area afforded 
by the porous PLGA microparticle caused more of the modified chitosan to be coated 
unto and in the interstitial layers of the particles. This in turn, resulted in a higher amount 
of 4-FPBA readily available for reaction with curcumin in the porous microparticle 
sample. This theory is further supported by the drastic colour change in the porous 
microparticle mixture upon addition of curcumin whereby the bright yellow colour of 
curcumin changed to orange due to the formation of rosocyanine complex. The intense 
colour change observed showed that significant rosocyanine complex was formed in the 
reaction between curcumin and porous microparticle sample and confirms a higher 
concentration of 4-FPBA was readily available for the reaction.  
A yield analysis was done to provide more insight into the glucose sensitivity of the two 
types of PLGA microparticle samples. The yield analysis quantifiably showed that a 
higher 4-FPBA content was obtained for the porous PLGA microparticle sample as 
compared to the non- porous sample. The yield analysis in this instance is related to the 
amount of 4-FPBA available for detection by curcumin. The porous microparticles, due 
to their porous microstructure, have a larger effective surface area for interaction with 
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curcumin and therefore should be more sensitive to glucose. On the other hand, the non-
porous microparticles with a relatively smaller size dimension should also offer a large 
surface area. The next section of study would shed some light on the relative dominance 
of these two factors.  4-FPBA and other boronic acid derivatives have a documented 
history of being sensitive to glucose and thus being developed as glucose sensing devices 
in the field of medical science (Jennifer N Cambre & Sumerlin 2011; Guan & Zhang 
2013). By measuring the 4-FPBA content in the PLGA microparticle through reaction 
with curcumin solution, the sensitivity of the microparticles towards glucose can be 
indirectly inferred. From HPLC and yield analyses, it was found that chitosan 
incorporated porous PLGA microparticles had a higher 4-FPBA content than the chitosan 
incorporated non-porous PLGA microparticle sample. We may affirm that the higher the 
4-FPBA content in the porous PLGA microparticles would manifest a higher sensitivity 
towards glucose but as mentioned earlier, the non-porous samples are relatively smaller 
in size and it would be interesting to observe the relative responses of the two types of 
microparticles to glucose. This is expanded further in the insulin release studies discussed 
in the next chapter.  
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6.0 ENCAPSULATION	AND	RELEASE	OF	INSULIN	FROM	MODIFIED	CHITOSAN	COATED	PLGA	MICROPARTICLES	
6.1 Introduction	
This chapter details the extent of insulin encapsulation in chitosan coated porous and 
non-porous PLGA microparticles. Further studies were done to investigate the insulin 
release profiles from both types of microparticles in glucose media in order to assess the 
relationship between insulin release and the glucose absorption capacity of the 
microparticles as a function of porosity. This constitutes the final aim of the study. 
The formulation of PLGA microparticles was achieved through the double solvent 
emulsion method (W1/O/W2). The method was chosen due to the ease with which 
hydrophilic drugs such as insulin can be incorporated easily within  the microparticles as 
well as the manifestation of sustained drug release rates studies (Hirenkumar & Siegel 
2012). The double solvent evaporation method involves first producing the water in oil 
phase (W1/O) by dissolving PLGA in the chosen solvent. At this stage, the model drug is 
usually added into the first water-in-oil phase prior to homogenization. Once the 
emulsification of the second phase (W1/O/W2) is achieved by the addition and 
homogenisation with the chosen surfactant, the drug should be encapsulated into the 
microparticle.  
The encapsulation efficiency in the double solvent- emulsion method for formulating 
drug loaded PLGA microparticles is normally high with studies reporting efficiencies 
ranging from 60 % to close to 100% with variation observed from case to case (Yang et 
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al. 2009; Dev et al. 2010). Yang et al. (2009) utilised a similar method to formulate 
porous PLGA microparticles for pulmonary drug delivery with lysozyme and 
doxorubicin as the model drugs with a remarkably high encapsulation efficiency 
(approximately 100% for both model drugs) (Yang et al. 2009). In another study, 
chitosan coated PLGA nanoparticles utilised the hydrophilic drug Lamivudine for anti-
HIV drug delivery applications reported a drug encapsulation efficiency of  
approximately 76% (Dev et al. 2010). Both studies showed the viability of drug 
encapsulation for PLGA particulates specifically formulated from the double solvent-
emulsion method. However, a study by Wang et al. (2013) on the investigation of 
chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery 
found that increasing the amount of chitosan in the formulation contributed to a lower 
drug encapsulation (Wang et al. 2013). Thus, in this study, it is expected that the drug 
encapsulation efficiency for PLGA microparticle to be lower than expected as well since 
a significant amount of chitosan (chitosan: PLGA ratio of 0.35:1) was used in the 
formulation to coat the microparticle.  
Various studies on the use of boronic acid and their derivatives to formulate glucose 
sensitive hydrogels reported that the hybrid gel showed considerable swelling termed 
‘glucose-dependent swelling behaviour' in the presence of glucose (Guan & Zhang 2013). 
This characteristic swelling can be detected by electrochemical means such as Faradaic 
impedance spectroscopy, chronopotentiometry and cyclic voltammetry which form the 
foundation for the development of glucose sensing devices (Guan & Zhang 2013).  
While glucose sensing devices and hybrid devices show promising developments, the 
relatively newer field of utilising similar boronic acid moieties for formulating glucose 
responsive microparticles for insulin delivery shows potential as well. It is postulated in 
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this study that the same swelling behaviour exhibited by glucose sensitive hydrogels can 
be exploited to the insulin loaded PLGA microparticles so that swelling of the 
microparticles can trigger the release of insulin. Therefore, with the demonstrable glucose 
sensitivity, these microparticles should exhibit insulin in the presence of glucose. The 
introduction of porosity to the microparticles, means that there is a large surface area 
available for interaction between glucose and the boronic acid moieties available on the 
surface and interstitium of the microparticles. This in turn we hope would orchestrate a 
responsive release of insulin. Thus, in this last and crucial objective of this study we hope 
to compare the insulin release profiles of these glucose responsive porous and non-porous 
PLGA microparticles in glucose solution. In accomplishing this objective, conclusions 
can then be drawn on the effects of glucose sensitivity of the microparticles on the insulin 
release.  
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6.2 Materials	and	Equipment	
Materials used for drug loading and release studies in addition to the materials required 
for PLGA microparticle formulation include HPLC grade acetonitrile and pure acetic 
acid obtained from Thermo Fischer Scientific (New Jersey, USA), Trifluoroacetic acid 
(TFA) acid 99% obtained from Sigma Aldrich (St.Louis,MO, USA), Insulin, recombinant 
human dry powder and Anhydrous D-(+)- Glucose was also obtained from Sigma 
Aldrich (St.Louis, MO, USA). Type one ultrapure Milli-QÒ Water (18.2 ohms at 250C) 
obtained from Merck Sdn. Bhd. (Selangor, Malaysia). 
 
Equipment used include HPLC (Perkin Elmer, Shelton, Connectticut, USA), HPLC 
column with the specification of Agilent Zorbax 300SB-4.6 x 250 mm C18, with particle 
size of 5 µm and pore size of 300 Å (Agilent Technologies, California, USA), Beckman 
Coulter Microfuge 16 centrifuge (Beckman Coulter, Inc., Indianapolis, USA), Beckman 
Benchtop Centrifuge (Allegra X-22R, Beckman Coulter, Inc., Indianapolis, USA).  
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6.3 Methods	
6.3.1 Formulation	of	insulin	loaded	PLGA	microparticles	
As insulin is only partially soluble in water, a more acidic solution was required to fully 
dissolve insulin powder. 5 mg of dry insulin powder was added into a 50 ml beaker 
containing 10 ml of 0.01 M acetic acid solution and was stirred thoroughly forming an 
insulin standard stock solution of 500 µg/ml. 1 ml of the insulin stock solution was then 
pipetted into a magnetically stirred chitosan solution which was then left stirring for 20 
minutes to ensure the mixture was well homogenous. The mixture was then added into 
the poly (vinyl alcohol) (PVA) surfactant solution and all further steps in the formulation 
is as described in section 4.3.1. Both porous and non-porous insulin loaded PLGA 
microparticles were formulated for insulin release study. 
 
6.3.2 HPLC	analyses	for	insulin	standard	solution	
Insulin in the PLGA microparticle samples were detected using a Perkin Elmer 
quaternary HPLC system equipped with a UV detector. The mobile phase was 0.1% 
aqueous triflouroacetic acid (TFA) (A) and 0.1% TFA in acetonitrile (B). TFA was added 
to the mobile phase at low concentration to ensure good peak shape was attainable in the 
chromatograph. It was reported that the use of TFA concentration of approximately 0.1% 
resulted in a good peak shape for most columns when used for the detection of insulin 
and other peptides (Carr 2016). While lowering the concentration of TFA further may 
improve the LC-MS detection sensitivity, it may result in poorly resolved peak shape 
especially for silica columns such as Agilent Zorbax due to the inherent purities in the 
silica surface (Carr 2016). A gradient elution of the mobile phase was used with mobile 
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phase A set to 75% of the total mobile phase and decreasing to 40% over 7 minutes at a 
flowrate of 1 ml/min. Insulin being protein would elute when the concentration of the 
organic solvent phase (B) increases to the precise concentration required for desorption 
(Carr 2016). In this case, isocratic elution is rarely useful for the separation of protein- 
based compounds like insulin because peaks obtained become broader and may result in 
loss in peak sharpness (Carr 2016). In addition, isocratic elution may cause large changes 
in the retention time if there is a small change in the organic solvent concentration of the 
mobile phase (Carr 2016). The injection volume was set at 20µl and the detection 
wavelength was set to 214 nm which falls in the UV absorption range for the most 
sensitive detection for polypeptides of all types. The calibration curve of insulin was 
constructed from insulin stock solution prepared at a range of 0 – 500 µg/ml. 
 
6.3.3 Determination	of	the	encapsulation	efficiencies	of	microparticles	
The encapsulation efficiency of insulin in the microparticles was determined using an 
indirect method. Instead of measuring the amount of drug entrapped within the 
microparticles, this indirect method relied on the free insulin present in the supernatant 
solution. The encapsulation efficiency was determined by separating the PLGA 
microparticles from the excess PVA solution containing free insulin. This was done by 
centrifugation at 4500 rpm for 20 minutes using Beckman Benchtop Centrifuge and 
supernatant was collected. The amount of drug present in the supernatant was measured 
using the HPLC procedure described in section 6.3.2 for detection of insulin which was 
then compared to the responses in the calibration curve. The drug present in the 
supernatant reflected the amount of unloaded drug which was used in equation 8 to 
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calculate the amount of encapsulated drug in the microparticle. The encapsulation 
efficiency of porous and non-porous PLGA microparticles was then compared.  
 !!	% = 	 (&'()*	+,-.*+,	+,	/'01.*)(+',-3044	+,-.*+,	+,	supernatant)>'()*	+,-.*+,	+,	/'01.*)(+', ×	100  ……………. (8) 
 
6.3.4 In	vitro	insulin	release	studies	
The insulin release studies are based upon the modified protocols in a study to determine 
the relationship between insulin release and glucose selectivity of multiboronic acid-
conjugated chitosan scaffolds (Siddiqui et al. 2017). The collected insulin loaded 
microparticles was lyophilised and stored in -200C after freeze drying before further 
analysis. Insulin loaded PLGA microparticles were studied in a glucose media in order to 
determine the relationship between glucose absorption capacity of the microparticles and 
insulin release.  Glucose solution was prepared by dissolving 30 mg of glucose in 10 ml 
of ultra-purified water to produce 3 mg/ml glucose solution. The glucose solution 
exhibited a pH value of 7 indicating neutrality as glucose does not dissociate to release 
H+ or OH- ions upon dissolving in the ultra-purified water. Several 10 mg replicas of 
chitosan coated porous and non-porous microparticle sample were placed in Eppendorf 
tubes containing 1 ml of glucose solution and incubated at 370C with horizontal shaking 
at 100 rpm on a WiseCube WIS-20, Precise Shaking Incubator. At set intervals of 10 
minutes, one of the Eppendorf tube from each sample was withdrawn and centrifuged at 
14000 rpm for 5 minutes using a Beckman Coulter Microfuge 16 centrifuge. The 
collected supernatant was then injected to the HPLC system. The amount of insulin 
released from the PLGA microparticles was determined by comparing the peak area 
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obtained with those in the calibration curve. The same procedure was repeated for 6 
intervals with each withdrawn tube being discarded after centrifugation. Each 
measurement was done in triplicates. 
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6.4 Results	and	Discussion	
6.4.1 HPLC	analysis	of	insulin	standard	solution	
The HPLC system was set up to detect insulin at a wavelength of 214 nm. Figure 25 
shows the chromatogram of insulin standard solution at 500 µg/ml after elution for 7 
minutes. It can be seen that there is one clearly resolved peak representing the insulin 
peak at an elution time of approximately 2.6 minutes.  
 
 
Figure	25:	Chromatogram	of	insulin	standard	solution	500	µg/ml 
	
The calibration curve was constructed from insulin standard solution range of 500 to 0 
µg/ml. The calibration curve obtained is presented in Figure 26. The curve was 
constructed by plotting the peak area with insulin concentration. It can be seen from the 
figure that the responses (peak area) are proportional to the insulin concentration which 
with a good linearity reflected by the coefficient of determination (R2) value of 0.999. 
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The standard curve was used to determine both the encapsulation efficiency of the 
microparticles as well as the insulin release profile of the samples.  
 
 
Figure	26:	Calibration	curve	for	insulin	standard	solution	0	-	500	µg/ml	
 
6.4.2 Encapsulation	efficiencies	of	porous	and	non-porous	insulin	loaded	
PLGA	microparticles		
Encapsulation efficiency gives an approximate indication of the amount of drug that was 
successfully entrapped within the PLGA microparticles during formulation. The amount 
of insulin entrapped in the microparticle sample was determined indirectly by measuring 
the amount in the supernatant. The encapsulation efficiency of insulin in porous and non-
porous PLGA microparticles is shown in Figure 27. 
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Figure	27:	Encapsulation	efficiency	of	non-porous	and	porous	PLGA	microparticle	
 
The encapsulation of insulin in both samples were relatively lower than reported values 
for other drugs including lamivudine (Dev et al. 2010), budesonide (Oh et al. 2011) and 
lysozyme (Yang et al. 2009) used in their PLGA microparticles. This is likely due to the 
method used for the incorporation of insulin into the microparticle formulation in the 
present investigation. As insulin is only partially soluble in water, 0.01M acetic acid was 
used to dissolve it (European Pharmacopoeia Commision 2005).  We did not incorporate 
the insulin solution in the primary emulsion because the low pH due to acetic acid would 
have reduced the overall negative charge within PLGA. This in would have compromised 
on the effectiveness of the positively charged 4-FPBA-chitosan interacting with the 
negatively charged PLGA and hence impact on the amount of 4-FPBA available. Thus, 
we decided to add insulin to the chitosan solution prior to homogenisation to form the 
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secondary emulsion with PVA surfactant. With this procedure however, the 
encapsulation efficiency of the microparticles to insulin was significantly affected by the 
presence of insulin in the aqueous phase. A significant amount of insulin may have 
leaked out of the microparticles to the PVA solution during the formation of the 
secondary emulsion and hardening process.  
The amount of chitosan in the formulation may potentially have also contributed to a 
decrease in  the encapsulation efficiency for insulin (Wang et al. 2013). This is because 
of the mutual attraction between the positively charged chitosan and the negatively 
charged insulin so that the amount of insulin incorporated within the microparticles was 
also dependant on the amount of chitosan incorporated (Koppolu 2015). This assertion is 
substantiated by Wang et al. (2013) who found that a higher chitosan concentration 
increased the likelihood of interaction between anionic proteins and cationic chitosan 
molecules prior to particle formation (Wang et al. 2013). Furthermore,  the same authors 
also postulated that this protein-chitosan binding resulted in lower encapsulation 
efficiency of the protein in PLGA nanoparticle formulations at the expense of  higher 
chitosan content (Wang et al. 2013). Through homogenisation and hardening of the 
microparticles as well as centrifugation for particle collection, some of the chitosan that 
contained adsorbed insulin may not have coated unto the surface of the microparticle and 
leaked out to the PVA solution which further decreased the encapsulation efficiency.  
Figure 27 shows that the encapsulation efficiency of non-porous PLGA microparticles 
was approximately 7% higher than the porous sample. The porous structure on the 
surface of the microparticle allowed some of the insulin entrapped within to easily leach 
out (Ilyas et al. 2013). Conversely, in the non-porous PLGA microparticles the 
encapsulated insulin was largely retained subsequent to formulation.  
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6.4.3 	In	vitro	insulin	release	studies	of	PLGA	microparticles	
Insulin release studies for the PLGA microparticles were conducted in glucose solution to 
determine the relationship between glucose absorption of the PLGA microparticle and 
insulin release. The glucose solution was set to 3 mg/ml to model the worst case scenario 
in blood glucose level of diabetic patient. Patients who suffer from diabetes Type 2 have 
fluctuating blood glucose level with peaks and valleys throughout the day and frequently 
experience a spike in blood glucose level around 2 hours after a meal with levels reaching 
200 mg/dl (2 mg/ml) or more (Diabetes UK 2017). In contrast, non-diabetics would only 
see a spike up to 140 mg/dl (1.4 mg/ml) after a meal (Diabetes UK 2017). With a 
relatively high glucose concentration, an in-vitro insulin release study would be vital in 
helping us decipher the performance of the porous and non-porous microparticles in 
severely high blood glucose level experienced by some diabetics. A faster response time 
reflected by a higher insulin release profile shows a higher sensitivity towards glucose. 
Figure 28 shows the insulin release profile for porous and non-porous PLGA 
microparticle samples.  
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Figure	28	:	Insulin	release	profile	for	porous	and	non-porous	PLGA	microparticle	formulations 
97		
Figure 28 shows that the insulin release profile for porous PLGA microparticle sample 
was consistently higher as compared to the non-porous sample. The initial insulin release 
from the porous PLGA microparticles (101.7 µg/ml) was approximately double that of 
the non-porous PLGA microparticle sample (50.9 µg/ml). However, after 20 minutes, the 
non-porous sample showed a drastic burst of insulin release (101.3 µg/ml) while the 
porous sample showed a more sustained release rate but retained a higher rate (111.9 
µg/ml) during that interval. Over the next 40 minutes, there was no further drastic release 
in both samples and the observed trend continued with a higher insulin release exhibited 
by the porous chitosan PLGA microparticles. The higher insulin release profile exhibited 
by the porous chitosan PLGA microparticles was primary due to the higher 4-FPBA 
content as presumed earlier. In aqueous systems, the boronic acid moieties in 4-FPBA 
exists in equilibrium with the neutral trigonal form (1) and the dissociated anionic 
tetrahedral form (2). The aqueous boronic acid moieties forms reversible and stable 
covalent complexes with 1,2 –diols or 1,3 –diols in glucose as shown in Figure 29 
(Jennifer N. Cambre & Sumerlin 2011). The conversion of neutral boronic acid moieties 
to anionic cyclic boronate ester (3) causes a change in the hydrophilicity of the overall 
polymer. This transition from neutral, hydrophobic PLGA polymer to a more hydrophilic 
polyanion results in the glucose swelling behaviour which is the precursor to insulin 
release  (Jennifer N. Cambre & Sumerlin 2011; Guan & Zhang 2013). As the 
concentration of boronic acid moiety increases in the system, the ratio of anionic 
boronate to boronate ester also increases with respect to neutral boronic acid moieties in 
the presence of the same diols resulting in a higher degree of change in the hydrophilicity 
of the polymer. Thus, the higher 4-FPBA content in the porous PLGA microparticles 
resulted in an increased swelling behaviour of the particles in response to glucose 
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solution and subsequently this swelling squeezes out any dislodged insulin which caused 
an increase in the diffusion rate of insulin from the microparticle. It must be added that 
the swelling eventually also causes an increase in path length for diffusing by insulin 
through the polymer network and this tends to slow down the rate of insulin release. This 
phenomenon seems to be operational after 40 mins when the insulin release appears more 
sustained. 
 
 
Figure	29:	Glucose	response	behavior	of	boronic	acid	moeities	
	
 
The higher insulin release observed in the porous PLGA microparticles can also be 
attributed to the inherent porosity of the microparticle. An increased in surface area for 
drug diffusion and better flow of fluid through a leaky interstitium resulted in a higher 
insulin release profile observed (Ilyas et al. 2013). Thus, a higher insulin release profile 
can be obtained by increasing the porosity of the microparticle.   
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6.5 Summary	
Insulin was successfully encapsulated into the microparticle by adding insulin into the 
chitosan solution and subsequently, into the PVA solution prior to the formation of the 
secondary emulsion. Encapsulation efficiency was determined based upon the indirect 
method of measuring the amount of free insulin in the supernatant. It was found that the 
encapsulation efficiency of the microparticles was lower than other reported studies and 
this could be due to the formation of insulin-chitosan which is then dictated by the 
concentration of chitosan in the microparticles. In addition, incorporating insulin in the 
secondary aqueous phase caused significant amount of insulin to leak out during particle 
formation and hardening. Overall, it was found that the encapsulation efficiency of the 
porous microparticles was lower than non-porous sample as entrapped insulin was more 
likely to flow out due to the porosity of the microparticle structure.  
The insulin release profile of the microparticles in glucose solution showed that higher 
insulin release was observed for porous PLGA microparticles. This is due to the higher 4-
FPBA content in the porous formulation which caused an increase in glucose swelling 
behaviour of the microparticles and consequently, increased the diffusion rate of insulin 
from the microparticle. In addition, more insulin was able to flow out due to the better 
flow of fluid afforded by the porosity of the microparticles. This results show that higher 
insulin release can be obtained by increasing the porosity and consequently, sensitivity of 
the PLGA microparticles towards glucose.  
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7.0 CONCLUSIONS	AND	FUTURE	WORK	
This study was successful in formulating chitosan coated PLGA microparticles for 
insulin delivery. The first main objective of this study was to impart glucose sensitivity 
characteristics to the PLGA microparticle. This was achieved by first conjugating 4 – 
formylphenyl boronic acid (4-FPBA) with chitosan. The successful conjugation of 4-
FPBA and chitosan proceed through N-reductive alkylation reaction by utilizing the 
Scifff’s base method. Through analytical methods including FTIR, FESEM and DSC 
analysis, several key observations were made. Through FTIR, it was found that the 
boronic acid moiety was bonded to the reactive primary amine site of the chitosan 
backbone. Furthermore, DSC analysis revealed that an increase in the degree of 
substitution in the conjugates was correlated to the consumption of the –NH2 group 
which provides a viable avenue for formulating conjugates with high amount of boronic 
acid content. Basically, by increasing the amount of 4-FPBA in the reaction, the resulting 
conjugates tends towards emulating the physical properties of pure 4-FPBA more than 
that of pure chitosan suggesting the physical properties of the conjugates were modified. 
This was further confirmed with FESEM imaging and showed that conjugated chitosan 
with high amount of boronic acid moieties were able to be formulated with relative ease.  
With the successful formulation of conjugated chitosan, the second objective of this study 
was to formulate porous and non-porous PLGA microparticles with chitosan coating. 
Double emulsion method was used to formulate the microparticles with modifications to 
incorporate the modified chitosan. Phosphate buffer saline (PBS) was used as a parogen 
to induce porosity to the microparticles and subsequent exposure to ethanolic- NaOH was 
done to enhance porosity. Through FESEM imaging, the formulated non-porous 
microparticles formulation showed spherical microparticles of relatively uniform sizes in 
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the range of 1.0 to 10.0 µm with no agglomeration. After porosity optimisation by 
adjusting the concentration of ethanolic –NaOH, the porous formulation obtained were 
spherical, stable with numerous pores observed on the surface.  
Glucose absorption of the PLGA microparticles was done through an indirect method 
utilising curcumin to detect 4-FPBA content in the microparticle samples. Higher amount 
of 4-FPBA correlates to a higher glucose sensitivity of the microparticles as observed in 
the insulin release studies. From HPLC analysis, the percentage of curcumin consumed 
by the porous PLGA microparticles was higher than the non-porous formulations which 
suggest that the increased in surface area afforded by the porous PLGA microparticle 
caused more of the modified chitosan to be incorporated unto the surface of the particle, 
thereby allowing a higher amount of 4-FPBA to be readily available for interaction with 
curcumin.  
Insulin release studies were then performed on both porous and non-porous PLGA 
microparticles to further define the relationship between the amount of insulin release and 
glucose sensitivity characteristic of the microparticles. From the insulin release profile 
obtained, porous PLGA microparticles showed a higher insulin release due to the higher 
amount of 4-FPBA content which caused an increased swelling of the microparticle in 
glucose solution, thereby releasing more of the insulin payload through diffusion. The 
more porous microstructure of the PLGA microparticle also played a role and allowed 
more insulin to flow out due to the better flow of fluid resulting in higher insulin release. 
Thus, the overall higher insulin release profile obtained for porous PLGA microparticle 
sample was achieved due to the higher glucose absorption characteristic afforded by high 
amount of 4-FPBA available as well as the porous microstructure afforded by the 
microparticle. 
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While all the objectives of this study were fulfilled, a number of issues remained that 
require further investigation. Low encapsulation efficiency of insulin presents a 
complication with the microparticles as high drug encapsulation is generally preferred to 
ensure viability of the PLGA microparticles in drug delivery applications. High 
encapsulation efficiency results in fewer microparticles needed to deliver the required 
dosage to the patient. Furthermore, a more comprehensive insulin release study is 
required to fully model the drug release profile of both types of microparticles. Drug 
loaded PLGA microparticles are known for having an initial burst release profile with a 
more sustained release after a few days. Burst release can then be enhanced or supressed 
depending on the objective by tuning specific parameters in the formulation. Thus, the 
new study should model the drug release over a prolonged amount of time to fully 
describe the drug release rate of the microparticles.  
 
 
 
 
 
 
 
103		
 
8.0 REFERENCES	
 
Abdel-Magid, A.F. et al., 1996. Reductive Amination of Aldehydes and Ketones with 
Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination 
Procedures1. The Journal of Organic Chemistry, 61(11), pp.3849–3862. Available 
at: http://dx.doi.org/10.1021/jo960057x. 
American Diabetes, A., 2012. Standards of Medical Care in Diabetes—2013. Diabetes 
Care, 36(Supplement 1), p.S11 LP-S66. Available at: 
http://care.diabetesjournals.org/content/36/Supplement_1/S11.abstract. 
American Diabetes, A., 2013. Standards of Medical Care in Diabetes—2014. Diabetes 
Care, 37(Supplement 1), p.S14 LP-S80. Available at: 
http://care.diabetesjournals.org/content/37/Supplement_1/S14.abstract. 
Arayne, M.S. & Sultana, N., 2006. Porous nanoparticles in drug delivery systems. Pak J 
Pharm Sci, 19(October), pp.158–169. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16751130. 
Asantewaa, Y. et al., 2013. Correlating Physicochemical Properties of Boronic Acid-
Chitosan Conjugates to Glucose Adsorption Sensitivity. Pharmaceutics, 5(1), 
pp.69–80. 
Birnbaum, D.T., Kosmala, J.D. & Brannon-peppas, L., 2000. Optimization of preparation 
techniques for poly ( lactic acid-co-glycolic acid ) nanoparticles. Nanoparticle 
Research, 2(2), pp.173–181. 
Blaine, R.L., 2015. Determination of Polymer Crystallinity by DSC. TA Instruments, 
pp.1–3. Available at: http://www.tainstruments.com/pdf/literature/TA123new.pdf 
[Accessed March 7, 2017]. 
Brooks, W.L.A. & Sumerlin, B.S., 2015. Synthesis and Applications of Boronic Acid-
Containing Polymers: From Materials to Medicine. Chemical Reviews, 
p.150914115935000. Available at: 
http://pubs.acs.org/doi/10.1021/acs.chemrev.5b00300. 
Cambre, J.N. & Sumerlin, B.S., 2011. Biomedical applications of boronic acid polymers. 
Polymer, 52(21), pp.4631–4643. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0032386111006495. 
Cambre, J.N. & Sumerlin, B.S., 2011. Biomedical applications of boronic acid polymers. 
Polymer, 52(21), pp.4631–4643. Available at: 
http://www.sciencedirect.com/science/article/pii/S0032386111006495. 
Carino, G.P., Jacob, J.S. & Mathiowitz, E., 2000. Nanosphere based oral insulin delivery. 
Journal of Controlled Release, 65(1–2), pp.261–269. Available at: 
http://www.sciencedirect.com/science/article/pii/S0168365999002473. 
104		
Carr, D., 2016. A Guide to the Analysis and Purification of Proteins and Peptides by 
Reversed-Phase HPLC. 
Chakraborty, C. et al., 2011. Landscape Mapping of Functional Proteins in Insulin Signal 
Transduction and Insulin Resistance: A Network-Based Protein-Protein Interaction 
Analysis. PLOS ONE, 6(1), p.e16388. Available at: 
http://dx.doi.org/10.1371%252Fjournal.pone.0016388. 
Chiranjib, C. et al., 2013. Nanoparticles as “smart” pharmaceutical delivery. Frontiers in 
Bioscience, 18, pp.1030–1050. 
Crotts, G. & Park, T.G., 1998. Protein delivery from poly(lactic-co-glycolic acid) 
biodegradable microspheres: Release kinetics and stability issues. Journal of 
Microencapsulation, 15(6), pp.699–713. Available at: 
http://dx.doi.org/10.3109/02652049809008253. 
De, S. & Robinson, D.H., 2004. Particle Size and Temperature Effect on the Physical 
Stability of PLGA Nanospheres and Microspheres Containing Bodipy. AAPS 
PharmSciTech, 5(4), pp.1–7. 
Dev, A. et al., 2010. Preparation of poly(lactic acid)/chitosan nanoparticles for anti-HIV 
drug delivery applications. Carbohydrate Polymers, 80(3), pp.833–838. Available 
at: http://www.sciencedirect.com/science/article/pii/S0144861710000020. 
Diabetes UK, 2017. Blood Sugar Level Ranges. Available at: 
http://www.diabetes.co.uk/diabetes_care/blood-sugar-level-ranges.html [Accessed 
April 20, 2017]. 
Ding, W. et al., 2003. Synthesis and characterization of a novel derivative of chitosan. 
Polymer, 44(3), pp.547–556. 
European Pharmacopoeia Commision, 2005. INSULIN , HUMAN Insulinum humanum. 
In EUROPEAN PHARMACOPOEIA. pp. 1800–1802. Available at: 
http://www.uspbpep.com/ep50/Insulin, human.pdf. 
Fan, L. & Singh, S.K., 1989. Controlled Release: A Quantitative Treatment, 
Fogler, H.S., 2006. Elements of chemical reaction engineering, 
Galant, A.L., Kaufman, R.C. & Wilson, J.D., 2015. Glucose : Detection and analysis q. 
Food Chemistry, 188, pp.149–160. Available at: 
http://dx.doi.org/10.1016/j.foodchem.2015.04.071. 
Guan, Y. & Zhang, Y., 2013. Boronic acid-containing hydrogels: synthesis and their 
applications. Chemical Society Reviews, 42(20), p.8106. Available at: 
http://xlink.rsc.org/?DOI=c3cs60152h. 
Guo, C. & Gemeinhart, R.A., 2008. Understanding the adsorption mechanism of chitosan 
onto poly(lactide-co-glycolide) particles. European Journal of Pharmaceutics and 
Biopharmaceutics, 70(2), pp.597–604. Available at: 
http://www.sciencedirect.com/science/article/pii/S0939641108002233. 
Hall, D.G., 2011. Structure , Properties , and Preparation of Boronic Acid Derivatives 
Overview of Their Reactions and Applications. 
105		
Hall, J.B. et al., 2007. Characterization of nanoparticles for therapeutics. Nanomedicine, 
2(6), pp.789–803. Available at: http://dx.doi.org/10.2217/17435889.2.6.789. 
Hirenkumar, M. & Siegel, S., 2012. PLGA as Biodegradable Drug Delivery Carrier. 
Polymers, 3(3), pp.1–19. 
Ilyas, A. et al., 2013. Salt-leaching synthesis of porous PLGA nanoparticles. IEEE 
Transactions on Nanotechnology, 12(6), pp.1082–1088. 
Kittur, F.S. et al., 2002. Characterization of chitin, chitosan and their carboxymethyl 
derivatives by differential scanning calorimetry. Carbohydrate Polymers, 49(2), 
pp.185–193. Available at: 
http://www.sciencedirect.com/science/article/pii/S0144861701003204. 
Klose, D. et al., 2006. How porosity and size affect the drug release mechanisms from 
PLGA-based microparticles. International Journal of Pharmaceutics, 314(2), 
pp.198–206. 
Koppolu, B. prasanth, 2015. Controlling chitosan-based encapsulation for protein and 
vaccine delivery. , 35(14), pp.4382–4389. 
Kumari, A., Yadav, S.K. & Yadav, S.C., 2010. Biodegradable polymeric nanoparticles 
based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), pp.1–
18. Available at: 
http://www.sciencedirect.com/science/article/pii/S0927776509004111. 
Lawrence, K. et al., 2012. Analytical Methods COMMUNICATION A simple and 
effective colorimetric technique for the detection of boronic acids and their 
derivatives †. , pp.2215–2217. 
Liu, J. et al., 2007. Controlled release of insulin from PLGA nanoparticles embedded 
within PVA hydrogels. Journal of Materials Science: Materials in Medicine, 18(11), 
pp.2205–2210. Available at: http://dx.doi.org/10.1007/s10856-007-3010-0. 
Lowman, A.M. et al., 2016. Oral delivery of insulin using pH&#x2010;responsive 
complexation gels. Journal of Pharmaceutical Sciences, 88(9), pp.933–937. 
Available at: http://dx.doi.org/10.1021/js980337n. 
Luan, X. et al., 2006. Key parameters affecting the initial release (burst) and 
encapsulation efficiency of peptide-containing poly(lactide-co-glycolide) 
microparticles. International Journal of Pharmaceutics, 324(2), pp.168–175. 
Available at: http://www.sciencedirect.com/science/article/pii/S0378517306004546. 
Matsumoto, M., Shimizu, T. & Kondo, K., 2002. Selective adsorption of glucose on 
novel chitosan gel modified by phenylboronate. Separation and Purification 
Technology, 29(3), pp.229–233. Available at: 
http://www.sciencedirect.com/science/article/pii/S1383586602000850. 
Murakami, H. et al., 1997. Influence of the degrees of hydrolyzation and polymerization 
of poly(vinylalcohol) on the preparation and properties of poly(dl-lactide-co-
glycolide) nanoparticle. International Journal of Pharmaceutics, 149(1), pp.43–49. 
Available at: http://www.sciencedirect.com/science/article/pii/S0378517396048545. 
Oh, Y.J. et al., 2011. Preparation of budesonide-loaded porous PLGA microparticles and 
106		
their therapeutic efficacy in a murine asthma model. Journal of Controlled Release, 
150(1), pp.56–62. Available at: 
http://www.sciencedirect.com/science/article/pii/S0168365910008990. 
Owens, D.R., Zinman, B. & Bolli, G.B., 2016. Insulins today and beyond. The Lancet, 
358(9283), pp.739–746. Available at: http://dx.doi.org/10.1016/S0140-
6736(01)05842-1. 
Polysciences, I., 2016. PLGA (Poly Lactic co- Glycolic Acid) Uniform Dry Microsphere, 
Available at: 
http://www.polysciences.com/skin/frontend/default/polysciences/pdf/TDS 858.pdf. 
Qutachi, O. et al., 2014. Injectable and porous PLGA microspheres that form highly 
porous scaffolds at body temperature. Acta Biomaterialia, 10(12), pp.5090–5098. 
Available at: http://www.sciencedirect.com/science/article/pii/S1742706114003511. 
Sahoo, S.K. et al., 2002. Residual polyvinyl alcohol associated with poly (d,l-lactide-co-
glycolide) nanoparticles affects their physical properties and cellular uptake. Journal 
of Controlled Release, 82(1), pp.105–114. Available at: 
http://www.sciencedirect.com/science/article/pii/S016836590200127X. 
Santucci, L. & Gilman, H., 1958. Some Bromine-containing and Sulfur-containing 
Aromatic Bornic Acids. Journal of the American Chemical Society, 80(1), pp.193–
196. Available at: http://dx.doi.org/10.1021/ja01534a048. 
Sharma, G. et al., 2015. Nanoparticle based insulin delivery system : the next generation 
efficient therapy for Type 1 diabetes. Journal of Nanobiotechnology, pp.1–13. 
Shrivastava, A. & Gupta, V., 2011. Methods for the determination of limit of detection 
and limit of quantitation of the analytical methods. Chronicles Young Scientist, 2(1), 
pp.21–25. 
Siddiqui, N.A., Billa, N. & Roberts, C.J., 2017. Multiboronic acid-conjugated chitosan 
scaffolds with glucose selectivity to insulin release. Journal of Biomaterials Science, 
Polymer Edition, 5063(March), p.0. Available at: 
http://dx.doi.org/10.1080/09205063.2017.1301774. 
Siepmann, J. et al., 2005. How Autocatalysis Accelerates Drug Release from PLGA-
Based Microparticles:  A Quantitative Treatment. Biomacromolecules, 6(4), 
pp.2312–2319. Available at: http://dx.doi.org/10.1021/bm050228k. 
Singh, M.N. et al., 2017. Microencapsulation : A promising technique for controlled drug 
delivery. , 5(2), pp.65–77. 
Singh, R. & Lillard Jr., J.W., 2009. Nanoparticle-based targeted drug delivery. 
Experimental and Molecular Pathology, 86(3), pp.215–223. Available at: 
http://www.sciencedirect.com/science/article/pii/S001448000800141X. 
Smoum, R., Rubinstein, A. & Srebnik, M., 2006. Chitosan−Pentaglycine−Phenylboronic 
Acid Conjugate:  A Potential Colon-Specific Platform for Calcitonin. Bioconjugate 
Chemistry, 17(4), pp.1000–1007. Available at: http://dx.doi.org/10.1021/bc050357y. 
Sun, S. et al., 2010. Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: 
Formulation, characterization and in vivo evaluation. Journal of 
107		
Microencapsulation, 27(6), pp.471–478. Available at: 
http://dx.doi.org/10.3109/02652040903515490. 
Wang, Y., Li, P. & Kong, L., 2013. Chitosan-Modified PLGA Nanoparticles with 
Versatile Surface for Improved Drug Delivery. AAPS PharmSciTech, 14(2), pp.585–
592. Available at: http://dx.doi.org/10.1208/s12249-013-9943-3. 
Wang, Z.H. et al., 2010. Trimethylated chitosan-conjugated PLGA nanoparticles for the 
delivery of drugs to the brain. Biomaterials, 31(5), pp.908–915. Available at: 
http://www.sciencedirect.com/science/article/pii/S0142961209010722. 
Webb, P.A., 2001. Volume and Density Determinations for Particle Technologists. , 
(February). 
Wu, J. et al., 2017. Insulin-loaded PLGA microspheres for glucose- responsive release. 
Drug Delivery, 24(1), pp.1513–1525. 
Yang, Y. et al., 2009. Biomaterials Development of highly porous large PLGA 
microparticles for pulmonary drug delivery. Biomaterials, 30(10), pp.1947–1953. 
Available at: http://dx.doi.org/10.1016/j.biomaterials.2008.12.044. 
Zhang, X. et al., 2012. Preparation and characterization of insulin-loaded bioadhesive 
PLGA nanoparticles for oral administration. European Journal of Pharmaceutical 
Sciences, 45(5), pp.632–638. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0928098712000255. 
 
 
 
 
108		
 
9.0 APPENDICES	
 9.1	FTIR	spectra	for	formulations	F2,	F4	and	F6	compared	to	pure	PBA	and	pure			chitosan.		
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